JP5248371B2 - 誘導多能性幹細胞を製造するための核初期化因子の使用 - Google Patents
誘導多能性幹細胞を製造するための核初期化因子の使用 Download PDFInfo
- Publication number
- JP5248371B2 JP5248371B2 JP2009056748A JP2009056748A JP5248371B2 JP 5248371 B2 JP5248371 B2 JP 5248371B2 JP 2009056748 A JP2009056748 A JP 2009056748A JP 2009056748 A JP2009056748 A JP 2009056748A JP 5248371 B2 JP5248371 B2 JP 5248371B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- gene
- genes
- cell
- ips
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title claims abstract description 39
- 230000008672 reprogramming Effects 0.000 title abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 245
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 58
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 32
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 27
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 26
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 26
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 25
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 22
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 14
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 7
- 239000000411 inducer Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 abstract description 203
- 108091057508 Myc family Proteins 0.000 abstract description 10
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 108700026220 vif Genes Proteins 0.000 abstract description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 83
- 238000000034 method Methods 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 22
- 210000002950 fibroblast Anatomy 0.000 description 18
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 241001430294 unidentified retrovirus Species 0.000 description 15
- 210000002257 embryonic structure Anatomy 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 210000002459 blastocyst Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004720 fertilization Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 101150072531 10 gene Proteins 0.000 description 6
- -1 Dnmt3L Proteins 0.000 description 6
- 101100011486 Mus musculus Elf4 gene Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 210000001626 skin fibroblast Anatomy 0.000 description 6
- 102000015735 Beta-catenin Human genes 0.000 description 5
- 108060000903 Beta-catenin Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 5
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 5
- 101710128836 Large T antigen Proteins 0.000 description 5
- 101150001847 Sox15 gene Proteins 0.000 description 5
- 239000002771 cell marker Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 210000002242 embryoid body Anatomy 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 102100037124 Developmental pluripotency-associated 5 protein Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000881848 Homo sapiens Developmental pluripotency-associated 5 protein Proteins 0.000 description 4
- 101000804949 Mus musculus Developmental pluripotency-associated protein 2 Proteins 0.000 description 4
- 101100390493 Mus musculus Fbxo15 gene Proteins 0.000 description 4
- 101150099493 STAT3 gene Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 210000002149 gonad Anatomy 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101150094083 24 gene Proteins 0.000 description 3
- 101150033839 4 gene Proteins 0.000 description 3
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 3
- 101000971801 Homo sapiens KH domain-containing protein 3 Proteins 0.000 description 3
- 101000889749 Homo sapiens Putative ATP-dependent RNA helicase TDRD12 Proteins 0.000 description 3
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 3
- 102100021450 KH domain-containing protein 3 Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 3
- 101000881849 Mus musculus Developmental pluripotency-associated protein 4 Proteins 0.000 description 3
- 101710150336 Protein Rex Proteins 0.000 description 3
- 102100040195 Putative ATP-dependent RNA helicase TDRD12 Human genes 0.000 description 3
- 101150047500 TERT gene Proteins 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 3
- 101000929049 Xenopus tropicalis Derriere protein Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 101150098203 grb2 gene Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000881866 Homo sapiens Developmental pluripotency-associated protein 3 Proteins 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- 101150002416 Igf2 gene Proteins 0.000 description 2
- 101150072501 Klf2 gene Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 2
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 2
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 101150024531 Slc7a1 gene Proteins 0.000 description 2
- 241000862969 Stella Species 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101150029857 23 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100038652 Ferritin heavy polypeptide-like 17 Human genes 0.000 description 1
- 101710138094 Ferritin heavy polypeptide-like 17 Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 101100355655 Mus musculus Eras gene Proteins 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- 101100404103 Mus musculus Nanog gene Proteins 0.000 description 1
- 101100137157 Mus musculus Pou5f1 gene Proteins 0.000 description 1
- 101100094847 Mus musculus Slc22a3 gene Proteins 0.000 description 1
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 1
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 102000037054 SLC-Transporter Human genes 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102200044943 rs121913400 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/605—Nanog
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Description
初期化因子を同定するためには初期化現象を容易に観察する実験系が必要である。実験系としてFbx15遺伝子座にβgeo(ベータガラクトシダーゼとネオマイシン耐性遺伝子の融合遺伝子)をノックインしたマウスを利用した。マウスFbx15遺伝子はES細胞や初期胚といった分化多能性細胞において特異的に発現する遺伝子である。しかしマウスFbx15遺伝子にβgeoをノックインし、Fbx15の機能を欠失したホモ変異マウスにおいては、分化多能性や発生を含めて異常な表現型は観察されなかった。このマウスにおいては、βgeoがFbx15遺伝子のエンハンサーやプロモーターにより発現制御される。すなわち、分化した体細胞ではβgeoは発現せず、G418に感受性を示す。一方、βgeoをノックインしたホモ変異ES細胞は極めて高濃度(12 mg/ml以上)のG418に耐性を示す。この現象を利用し、体細胞の初期化を可視化する実験系を構築した。
10種類の遺伝子群のなかで特に重要性が示唆された4遺伝子により体細胞の初期化の誘導が可能であるか否かを検討した。Fbx15遺伝子にβgeoをノックインしたMEF細胞に上記10種類の遺伝子の組み合わせ、上記4種類の遺伝子の組み合わせ、上記4種類のうち3種類のみの遺伝子の組み合わせ、及び上記4種類のうち2種類のみの遺伝子の組み合わせを用いて、これらの遺伝子群をレトロウイルスにより体細胞に導入した。その結果、4種類の遺伝子を導入した場合には160個のG418耐性コロニーが得られた。この結果は、10種類の遺伝子を導入した場合の結果(179コロニー)とほぼ同数であったが、4遺伝子導入の場合には10遺伝子導入の場合に比べてコロニーが小さかった。また、これらのコロニーを継代培養した場合、iPS細胞の形態を示したコロニーは10遺伝子導入の場合に12クローン中9クローンであったのに対して、4遺伝子導入の場合には12クローン中7クローンと若干少ない傾向にあった。4遺伝子としては、マウス由来のもの、ヒト由来のもの、どちらでもほぼ同じ数のiPS細胞が得られた。
樹立したiPS細胞の分化多能性を評価するため、24因子、10因子、および4因子で樹立されたiPS細胞をヌードマウスの皮下に移植した。その結果、ES細胞と同様の大きさの腫瘍が全例で形成された。組織学的に見ると腫瘍は複数の種類の細胞から構成されており、軟骨組織、神経組織、筋肉組織、脂肪組織、および腸管様組織(図8)が認められたことから、iPS細胞の多能性が証明された。一方、3因子で樹立した細胞をヌードマウスに移植すると腫瘍は形成されたが、組織学的には未分化細胞からのみ形成されていた。したがって、分化多能性の誘導のためには、Soxファミリーが必須であることがわかった。
マウス胎児線維芽細胞(MEF)で同定した4因子をFbx15遺伝子にβgeoをノックインし、さらに全身で緑色蛍光蛋白質(GFP)を発現する成体マウスの尾部に由来する線維芽細胞に導入した。その後、フィーダー細胞上でES細胞培養条件と同様の条件で培養してG418による選択を行った。薬剤選択開始後約2週間で複数のiPS細胞コロニーが得られた。これらの細胞をヌードマウスの皮下に移植すると三胚葉系の様々な組織からなる奇形腫を形成した。また成体皮膚線維芽細胞に由来するiPS細胞を胚盤胞に移植し、偽妊娠マウスの子宮に移植したところ、受精後13.5日目の胚において、全身でGFP陽性細胞の分布しているものが認められた(図9)。これはiPS細胞が多能性を有しており、マウス胚発生に寄与できることを示している。この結果は、同定した因子群が胎児期の体細胞だけではなく成熟したマウスの体細胞に対しても初期化を誘導する能力のあることを示している。成体皮膚由来の細胞で初期化誘導できることは実用上極めて重要である。
iPS細胞樹立におけるサイトカインの影響を検討した。フィーダー細胞(STO細胞)に塩基性線維芽細胞増殖因子(bFGF)又は幹細胞因子(SCF)の発現ベクター(pMXレトロウイルスベクター)を導入し、これらのサイトカインを恒常的に発現する細胞を樹立した。Fbx15βgeo/βgeoマウス由来MEF(50万個/100mmディッシュ)をこれらのSTO細胞上で培養し、4因子を導入後G418 による選択を行ったところ、通常のSTO細胞上で培養した時と比べて、コロニー形成数がbFGF(図11)、SCF(data not shown)を産生するSTO細胞上では20倍以上上昇した。またc-Myc以外の3因子を導入しても通常のSTO細胞上ではiPS細胞コロニーは精製されなかったが、bFGF(図11)、SCF(data not shown)を産生するSTO細胞上では、コロニーの形成が認められた。これらの結果から、サイトカインの刺激により、MEFからのiPS細胞の樹立効率が上昇すること、及びc-Mycに換えてサイトカインを用いることにより核初期化が可能になることが明らかとなった。
Oct3/4、Klf4、c-Myc、及びSox2遺伝子にはすべてファミリー遺伝子(表1及び2)が存在する。そこで4遺伝子に換えてファミリー遺伝子によってもiPS細胞が樹立できるかを検討した。表7に2回の実験の結果を合わせたものを示す。Soxファミリーについては、Sox1はG418耐性コロニー数及びiPS細胞樹立効率とともにSox2と同程度であった。Sox3はG418耐性コロニー数はSox2の10分の1程度であったが、ひろったコロニーからのiPS細胞樹立効率はSox2よりむしろ高かった。Sox15はG418耐性コロニー数及びiPS細胞樹立効率とともにSox2より低かった。Sox17はG418耐性コロニーはSox2と同程度であったが、iPS細胞樹立効率は低かった。Klfファミリーについては、Klf2はKlf4より少ないG418耐性コロニーが生じたが、iPS細胞の樹立効率は同程度であった。Mycファミリーについては、まず野生型のc-MycがT58A変異体とG418耐性コロニー数、iPS細胞樹立効率の両者において同程度であることを確認した。さらにN-Myc及びL-Myc(ともに野生型)は、ともにc-MycとG418耐性コロニー数、iPS細胞樹立効率の両者において同程度であった。
Fbx15-βgeo以外のレポーターでiPS細胞が樹立できるかを検討した。まずNanog遺伝子を中央部に含む大腸菌人工染色体(BAC)を単離し、大腸菌内の組み換えにより、GFP遺伝子及びピューロマイシン耐性遺伝子をノックインした(図12A)。ついで同改変BACをES細胞に導入し、未分化状態特異的にGFP陽性となることを確認した(data not shown)。ついで同ES細胞のマウス胚盤胞に移植することによりキメラマウスを経てトランスジェニックマウスを作出した。このマウスにおいてはGFP陽性細胞は胚盤胞の内部細胞塊や受精後13.5日胚の生殖腺において特異的に認められた(図12B)。受精後13.5日胚(DBA、129及びC57BL/6マウスの雑種)から生殖腺を除去し、MEFを単離した。フローサイトメトリーにより、単離したMEFはGFP陰性であることを確認した(図13)。このMEFに4因子をレトロウイルスで導入し、ピューロマイシンによる選択を行ったところ、複数の耐性コロニーが得られた。その中の約10〜20%のみがGFP陽性であった。GFP陽性コロニーを継代培養するとES細胞に類似した形態(図14)や増殖(図15)を示した。また遺伝子発現を見るとFbx15βgeo/βgeoのMEFからG418選択により単離したiPS細胞より、さらにES細胞に近い発現パターンであることがわかった(図16)。この細胞をヌードマウスに移植すると奇形腫が形成されたことからiPS細胞であることが確認された(図17)。さらにNanog-GFP選択によるiPS細胞をC57BL/6マウスの胚盤胞に移植することによりキメラマウスが誕生した(図18)。さらにこのキメラマウス同士を交配させることによりジャームライントランスミッションが確認された(図19)。このNanog-GFP選択により樹立されたよりES細胞に近いiPS細胞においては、レトロウイルスからの4因子の発現はほぼ完全にサイレンシングを受けており、内在性のOct3/4やSox2により自己複製が維持されていることが示唆された。
10cm コンフルエントのiPS細胞を、トリプシン処理し、ES 細胞用培地に懸濁した(STO細胞は懸濁後10〜20分ゼラチンコートしたディッシュに接着させることによって除去した)。2×106の細胞を、HEMA(2-hydroxyethyl methacrylate)でコーティングした大腸菌培養用ディッシュで4日間浮遊培養し、Embryoid body(EB)を形成させた(day1-4)。EB形成4日目(day 4)に、EBを全量10cm組織培養用ディッシュに移しES 細胞用培地で24時間培養して接着させた。24時間後(day 5)にITS/fibronectin含有培地に交換した。7日間培養し(2日毎に培地交換を行う)、nestin 陽性細胞を選択した(無血清下で培養すると、他の系譜の細胞がある程度死んでいく)(day5-12)。次にA2B5陽性細胞の誘導を行った。7日後(day 12)にトリプシン処理して細胞をばらばらにし、残存するEBは除去した。1×105個の細胞をpoly-L-ornithine/fibronectinがコーティングされている 24ウェルプレートに撒き、N2/ bFGF 含有培地で四日間培養した(二日毎に培地交換(day12-16)。四日後(day 16)にN2/bFGF/EGF 含有培地へ交換し、四日間培養した(二日毎に培地交換)(day16-20)。四日後(day 20)にN2/bFGF/PDGF含有培地 に交換して、四日間培養した(二日毎に培地交換)(day20-24)。この期間(day12-24)に細胞が増えすぎてコンフルエントになった場合は随時継代し、1〜2×105個の細胞を撒いた。(継代時期によって数は変更する)。四日後(day 24)にN2/T3 培地 に交換して、7日間培養し(day24-31)し、2日毎に培地交換を行った。day 31に固定し、免疫染色した。その結果、iPS細胞から、βIIIチュブリン陽性の神経細胞、O4陽性のオリゴデンドロサイト、GFAP陽性のアストロサイトへの分化が確認された(図20)。
Fbx15-βgeoノックインマウス以外の任意のマウス体細胞からiPS細胞を樹立するために、薬剤選択を用いない樹立方法を開発した。10cmディッシュ(STOフィーダー細胞上)にマウス胎児線維芽細胞(MEF)を、これまでより少数(1万、5万又は10万個)培養し、レトロウイルスによりコントロールDNA又は4因子を導入した。ES細胞培地にて2週間培養(G418選択無し)行ったところ、コントロールDNAを導入したディッシュではコロニー形成が認められなかったが、4因子を導入したディッシュにおいては形質転換したと思われる扁平なコロニー加えて、複数のコンパクトなコロニーが形成された(図21)。これらから24コロニーをピックアップし培養を続けたところ、ES細胞様の形態が認められた。その遺伝子発現をRT-PCRにて検討したところ、7クローンにおいてES細胞マーカーであるEsg1の発現が認められた。またクローン4においてはNanog、ERas、GDF3、Oct3/4、Sox2などの多くのES細胞マーカーの誘導が認められたことからiPS細胞であると考えられた(図 22)。以上の結果より、iPS細胞樹立にはFbx15-βgeoノックインなどを用いた薬剤選択は必須でなく、任意のマウス由来体細胞からiPS細胞を樹立できることが示された。本技術により疾患モデルマウスの体細胞からもiPS細胞が樹立できる可能性が示された。
iPS細胞を誘導する細胞として、線維芽細胞以外の細胞である、肝細胞及び胃粘膜細胞を検討した。Fbx15βgeo/βgeoマウスの肝臓から肝細胞を還流により単離した。この肝細胞に4因子をレトロウイルスで投与し、G418による選択を行ったところ複数のiPS細胞コロニーが得られた。DNAマイクロアレーによる遺伝子発現パターン解析の結果、肝臓由来のiPS細胞は皮膚線維芽細胞や胎児線維芽細胞由来のiPS細胞より、さらにES細胞に類似していることが明らかとなった。胃粘膜細胞からも、肝細胞からと同様にiPS細胞が得られた。
PD98059はMAPキナーゼの阻害薬であり、多くの分化細胞においては増殖を抑制するが、ES細胞においては、未分化状態維持と増殖を促進することが知られている。そこでiPS細胞樹立におけるPD98059の効果を検討した。Nanog-EGFP-IRES-Puroの選択マーカーをもつマウスから樹立したMEFに4因子をレトロウイルスで投与し、ピューロマイシンによる選択を行った。PD98059を投与しない場合、得られたiPS細胞コロニーの中で、GFP陽性の割合は8%であった。一方、PD98059(最終濃度25μM)をレトロウイルス感染の翌日から持続的に投与した群では、得られたコロニーの45%がGFP陽性であった。これはPD98059がGFP陽性の、よりES細胞に近いiPS細胞の増殖を促進するが、GFP陰性のiPS細胞や、分化細胞の増殖は抑制するためであると考えられた。このことからPD98059は、よりES細胞に近いiPS細胞の樹立や、薬剤選択を用いないiPS細胞の樹立に利用できることが示された。
胎児由来のHuman dermal fibroblast (HDF) にマウスエコトロピックウイルスレセプターであるsolute carrier family 7(Slc7a1、NCBIアクセッション番号NM_007513)をレンチウイルスで発現させた細胞に、マウスOct3/4遺伝子プロモーター下流に赤色蛍光蛋白質遺伝子を、およびPGKプロモーター下流にハイグロマイシン耐性遺伝子を組み込んだプラスミドをヌクレオフェクションで導入した。ハイグロマイシンによる選択を行い、安定発現株を樹立した。800000個の細胞をマイトマイシン処理したSTO細胞の上にまき、翌日レトロウイルスによりOct3/4, Sox2, Klf4, c-Myc(いずれもヒト由来)を導入した。3週間後に得られたコロニー(図23左)を24個拾い、STO細胞を播種した24-well plateに移して培養した。2週間後に増えてきた1クローンをSTO細胞を播種した6-well plateに継代して培養した結果、ES細胞に形態上において類似した細胞が得られ(図23右)、iPS細胞であることが示唆された。培地は常にマウスES細胞用培地を用いた。
ヒト成体皮膚線維芽細胞(adult HDF) にレンチウイルスでSlc7a1(マウスレトロウイルス受容体)を導入した細胞を800000個のフィーダー細胞(マイトマイシン処理STO細胞)上にまき、以下の組み合わせでレトロウイルスにより遺伝子を導入した。
1. Oct3/4, Sox2, Klf4, c-Myc, TERT, SV40 Large T antigen
2. Oct3/4, Sox2, Klf4, c-Myc, TERT, HPV16 E6
3.Oct3/4, Sox2, Klf4, c-Myc, TERT, HPV16 E7
4. Oct3/4, Sox2, Klf4, c-Myc, TERT, HPV16 E6, HPV16 E7
5. Oct3/4, Sox2, Klf4, c-Myc, TERT, Bmi1
(Oct3/4, Sox2, Klf4, c-Myc, TERTはヒト由来、Bmi1はマウス由来)
マウスES細胞の培養条件下で、薬剤選択無しで培養を続けたところ、1の組み合わせで因子を導入したディッシュにおいて、ウイルス感染8日後において、iPS細胞と思われるコロニーが出現した(図24)。他の組み合わせ(2から5)においても、1の組み合わせの場合ほどは明瞭ではないが、iPS細胞様のコロニーが出現した。4因子のみを導入しても、全くコロニーは出現しなかった。
Claims (5)
- 塩基性線維芽細胞増殖因子の存在下で、体細胞から誘導多能性幹細胞を製造するための、Oct3/4、Klf4およびSox2の3種の遺伝子、またはそれらの遺伝子産物の使用。
- 体細胞から誘導多能性幹細胞を製造するための、Oct3/4、Klf4、c-MycおよびSox2の4種の遺伝子、またはそれらの遺伝子産物の使用。
- Oct3/4、Klf4およびSox2の3種の遺伝子、またはそれらの遺伝子産物を成分として含む、体細胞から誘導多能性幹細胞へ、塩基性線維芽細胞増殖因子の存在下で培養して誘導するための、誘導剤。
- Oct3/4、Klf4、c-MycおよびSox2の4種の遺伝子、またはそれらの遺伝子産物を成分として含む、体細胞から誘導多能性幹細胞への誘導剤。
- 上記成分を構成する遺伝子が1以上のベクターに導入されている、請求項3または4記載の誘導剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009056748A JP5248371B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞を製造するための核初期化因子の使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005359537 | 2005-12-13 | ||
JP2005359537 | 2005-12-13 | ||
JP2009056748A JP5248371B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞を製造するための核初期化因子の使用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007550210A Division JP5098028B2 (ja) | 2005-12-13 | 2006-12-06 | 核初期化因子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009165479A JP2009165479A (ja) | 2009-07-30 |
JP5248371B2 true JP5248371B2 (ja) | 2013-07-31 |
Family
ID=38162968
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007550210A Active JP5098028B2 (ja) | 2005-12-13 | 2006-12-06 | 核初期化因子 |
JP2008131577A Active JP4183742B1 (ja) | 2005-12-13 | 2008-05-20 | 誘導多能性幹細胞の製造方法 |
JP2009056750A Active JP4411363B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞からの体細胞の製造方法 |
JP2009056747A Active JP4411362B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞の製造方法 |
JP2009056748A Active JP5248371B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞を製造するための核初期化因子の使用 |
JP2009056749A Active JP5467223B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞およびその製造方法 |
JP2011088113A Active JP5603282B2 (ja) | 2005-12-13 | 2011-04-12 | 誘導多能性幹細胞 |
JP2013167725A Active JP5943324B2 (ja) | 2005-12-13 | 2013-08-12 | 誘導多能性幹細胞 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007550210A Active JP5098028B2 (ja) | 2005-12-13 | 2006-12-06 | 核初期化因子 |
JP2008131577A Active JP4183742B1 (ja) | 2005-12-13 | 2008-05-20 | 誘導多能性幹細胞の製造方法 |
JP2009056750A Active JP4411363B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞からの体細胞の製造方法 |
JP2009056747A Active JP4411362B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞の製造方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009056749A Active JP5467223B2 (ja) | 2005-12-13 | 2009-03-10 | 誘導多能性幹細胞およびその製造方法 |
JP2011088113A Active JP5603282B2 (ja) | 2005-12-13 | 2011-04-12 | 誘導多能性幹細胞 |
JP2013167725A Active JP5943324B2 (ja) | 2005-12-13 | 2013-08-12 | 誘導多能性幹細胞 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8048999B2 (ja) |
EP (6) | EP2206724A1 (ja) |
JP (8) | JP5098028B2 (ja) |
KR (1) | KR101420740B1 (ja) |
CN (4) | CN103113463B (ja) |
AU (1) | AU2006325975B2 (ja) |
BR (1) | BRPI0619794B8 (ja) |
CA (1) | CA2632142C (ja) |
DK (1) | DK1970446T3 (ja) |
EA (2) | EA018039B1 (ja) |
ES (1) | ES2367525T3 (ja) |
HK (2) | HK1125131A1 (ja) |
IL (1) | IL191903A (ja) |
MX (2) | MX2008007654A (ja) |
NZ (1) | NZ569530A (ja) |
PT (1) | PT1970446E (ja) |
WO (1) | WO2007069666A1 (ja) |
ZA (1) | ZA200804673B (ja) |
Families Citing this family (570)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
WO2005098425A1 (en) | 2004-04-07 | 2005-10-20 | Axiogenesis Ag | Non-invasive, in vitro functional tissue assay systems |
EP3070174B1 (en) | 2004-05-11 | 2019-11-06 | Ncardia AG | Drug discovery based on in vitro differentiated cells |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
ES2836764T3 (es) * | 2005-08-03 | 2021-06-28 | Astellas Inst For Regenerative Medicine | Métodos mejorados de reprogramación de células somáticas animales |
US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
US9157066B2 (en) | 2005-12-13 | 2015-10-13 | The Trustees Of The University Of Pennsylvania | Transcriptome transfer produces cellular phenotype conversion |
US20090227032A1 (en) * | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
DK3467112T3 (da) | 2005-12-13 | 2020-11-30 | Univ Pennsylvania | Fremgangsmåder til transfektion af nukleinsyrer til levende celler |
US10647960B2 (en) | 2005-12-13 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Transcriptome transfer produces cellular phenotype conversion |
SG170065A1 (en) | 2006-03-06 | 2011-04-29 | Agency Science Tech & Res | Human embryonic stem cell methods and podxl expression |
CN101679950A (zh) * | 2007-02-22 | 2010-03-24 | 国立大学法人东京大学 | 利用胚泡互补的器官再生法 |
EP2137296A2 (en) * | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
MX348010B (es) * | 2007-04-07 | 2017-05-23 | Whitehead Inst Biomedical Res | Reprogramacion de celulas somaticas. |
AU2016216711B2 (en) * | 2007-04-07 | 2018-01-25 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
CN101772580B (zh) * | 2007-05-29 | 2015-11-25 | 克里斯多佛·B·里德 | 专能细胞群的生产和使用方法 |
JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
RU2473685C2 (ru) | 2007-07-31 | 2013-01-27 | Лайфскен, Инк. | Дифференцировка человеческих эмбриональных стволовых клеток |
US20120282229A1 (en) * | 2007-08-01 | 2012-11-08 | Christian Kannemeier | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
ES2589122T3 (es) | 2007-08-31 | 2016-11-10 | Whitehead Institute For Biomedical Research | Estimulación de la ruta de la Wnt en la reprogramación de células somáticas |
WO2009057831A1 (ja) * | 2007-10-31 | 2009-05-07 | Kyoto University | 核初期化方法 |
CN101878298B (zh) | 2007-11-27 | 2017-08-15 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
WO2009073523A2 (en) * | 2007-11-29 | 2009-06-11 | Children's Hospital Of Orange County | De-differentiation of human cells |
AU2008286249B2 (en) * | 2007-12-10 | 2013-10-10 | Kyoto University | Efficient method for nuclear reprogramming |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
JP5626619B2 (ja) * | 2008-12-08 | 2014-11-19 | 国立大学法人京都大学 | 効率的な核初期化方法 |
EP2235161A1 (en) | 2007-12-11 | 2010-10-06 | Research Development Foundation | Small molecules for neuronal differentiation of embryonic stem cells |
EP2072618A1 (en) * | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
KR101481164B1 (ko) * | 2008-01-30 | 2015-01-09 | 주식회사 미래셀바이오 | 체세포 유래 다능성 줄기세포의 제조 방법 |
WO2009096049A1 (ja) * | 2008-02-01 | 2009-08-06 | Kyoto University | 人工多能性幹細胞由来分化細胞 |
CN105886459A (zh) | 2008-02-21 | 2016-08-24 | 詹森生物科技公司 | 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物 |
JP5688788B2 (ja) * | 2008-02-22 | 2015-03-25 | 国立大学法人 東京大学 | 遺伝子改変による致死性表現型を持つ動物の繁殖用ファウンダー動物作製法 |
JP2009215191A (ja) | 2008-03-07 | 2009-09-24 | Keio Gijuku | 神経損傷治療剤及び神経損傷治療方法 |
EP2100954A1 (en) * | 2008-03-10 | 2009-09-16 | Assistance Publique - Hopitaux de Paris | Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications |
AU2009225665B9 (en) | 2008-03-17 | 2015-01-15 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
AU2015201026B2 (en) * | 2008-03-17 | 2017-03-16 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
WO2009114949A1 (en) * | 2008-03-20 | 2009-09-24 | UNIVERSITé LAVAL | Methods for deprogramming somatic cells and uses thereof |
WO2009118928A1 (en) * | 2008-03-26 | 2009-10-01 | Kyoto University | Efficient production and use of highly cardiogenic progenitors and cardiomyocytes from embryonic and induced pluripotent stem cells |
JPWO2009119105A1 (ja) * | 2008-03-28 | 2011-07-21 | 国立大学法人 東京大学 | GPIbα+GPV+GPVI+血小板のインビトロ調製法 |
US20110117645A1 (en) * | 2008-03-31 | 2011-05-19 | Oriental Yeast Co., Ltd. | Method for proliferation of pluripotent stem cells |
JP5617631B2 (ja) * | 2008-04-01 | 2014-11-05 | 国立大学法人東京大学 | iPS細胞からの血小板の調製方法 |
WO2009146098A2 (en) * | 2008-04-02 | 2009-12-03 | President And Fellows Of Harvard College | Stem cells and uses thereof |
CN102083968A (zh) * | 2008-04-07 | 2011-06-01 | 纽珀滕索有限公司 | 通过使用小分子调节剂诱导复能基因而重编程细胞 |
US20100021437A1 (en) * | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
KR101481165B1 (ko) * | 2008-04-25 | 2015-01-09 | 주식회사 미래셀바이오 | 인간 체세포 유래 다능성 줄기세포의 제조 방법 |
EP2268809B1 (en) | 2008-05-02 | 2019-02-06 | Kyoto University | Method of nuclear reprogramming |
EP2283118A4 (en) * | 2008-05-06 | 2012-11-21 | Agency Science Tech & Res | METHOD FOR REALIZING THE DIFFERENTIATION OF A CELL |
WO2009137844A2 (en) * | 2008-05-09 | 2009-11-12 | Vistagen Therapeutics, Inc. | Pancreatic endocrine progenitor cells derived from pluripotent stem cells |
WO2009142717A2 (en) * | 2008-05-19 | 2009-11-26 | President And Fellows Of Harvard College | Methods and products for dedifferentiation of cells |
EP2128245A1 (en) | 2008-05-27 | 2009-12-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Generation of induced pluripotent stem (iPS) cells |
JP2011160661A (ja) * | 2008-06-02 | 2011-08-25 | Kyowa Hakko Kirin Co Ltd | 血球細胞の初期化法 |
EP3112456A1 (en) * | 2008-06-04 | 2017-01-04 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using non-viral approach |
US9497943B2 (en) * | 2008-06-13 | 2016-11-22 | Whitehead Institute For Biomedical Research | Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides |
AU2015202237B2 (en) * | 2008-06-13 | 2017-09-28 | Whitehead Institute For Biomedical Research | Programming and reprogramming of cells |
WO2010008486A2 (en) * | 2008-06-24 | 2010-01-21 | Parkinsons Institute | Pluripotent cell lines and methods of use thereof |
JP2011525794A (ja) * | 2008-06-26 | 2011-09-29 | 国立大学法人大阪大学 | iPS細胞の製造方法および製造キット |
WO2009157610A1 (en) * | 2008-06-26 | 2009-12-30 | Pusan National University Industry-University Cooperation Foundation | Selenium dedifferentiated cell, preparation method and usage thereof |
SG10201402428WA (en) | 2008-06-27 | 2014-07-30 | Univ Kyoto | Method of efficiently establishing induced pluripotent stem cells |
KR101829310B1 (ko) | 2008-06-30 | 2018-02-14 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 분화 |
EP3075850B1 (en) | 2008-07-16 | 2019-02-06 | ID Pharma Co., Ltd. | Method for production of reprogrammed cell using chromosomally unintegrated virus vector |
JP5562231B2 (ja) | 2008-07-30 | 2014-07-30 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
KR101372752B1 (ko) * | 2008-07-31 | 2014-03-14 | 고꾸리츠 다이가꾸호오징 기후다이가꾸 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
EP2321406B1 (en) * | 2008-08-05 | 2014-12-10 | Keio University | Method for selecting secondary neurosphere derived from induced pluripotent stem cell |
EP2315829B1 (en) * | 2008-08-08 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Induced pluripotent stem cells |
KR101773345B1 (ko) * | 2008-08-12 | 2017-08-31 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | iPS 세포의 생산 방법 |
EA201170352A1 (ru) * | 2008-08-21 | 2011-08-30 | Рихтер Гедеон Нирт. | Способы лечения расстройств цнс |
CN102196722A (zh) * | 2008-08-22 | 2011-09-21 | 国立大学法人东京大学 | 利用iPS细胞和胚泡互补的器官再生法 |
WO2010027062A1 (ja) | 2008-09-04 | 2010-03-11 | 独立行政法人理化学研究所 | B細胞由来iPS細胞およびその用途 |
JP5709751B2 (ja) * | 2008-09-04 | 2015-04-30 | エイビーティー ホールディング カンパニー | ニューロンの軸索退縮を予防するための幹細胞の使用 |
EP2336303B1 (en) * | 2008-09-08 | 2015-07-15 | Riken | NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM |
WO2010030986A2 (en) * | 2008-09-12 | 2010-03-18 | Scarab Genomics, Llc | Clean genome bactofection |
CN101492676B (zh) * | 2008-09-16 | 2011-02-16 | 中国科学院广州生物医药与健康研究院 | 用脑膜细胞生成诱导的多能性干细胞的方法及其用途 |
SG160248A1 (en) * | 2008-09-18 | 2010-04-29 | Agency Science Tech & Res | Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells |
US8703413B2 (en) | 2008-09-22 | 2014-04-22 | Children's Medical Center Corporation | Detection of human somatic cell reprogramming |
JP5676265B2 (ja) * | 2008-10-24 | 2015-02-25 | 株式会社クラレ | 細胞保存方法、及び細胞輸送方法 |
WO2010050626A1 (en) * | 2008-10-30 | 2010-05-06 | Kyoto University | Method for producing induced pluripotent stem cells |
EP2350265B1 (en) | 2008-10-31 | 2019-04-17 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
ES2634445T3 (es) | 2008-10-31 | 2017-09-27 | Janssen Biotech, Inc. | Diferenciación de las células madre embrionarias humanas con el linaje endocrino pancreático |
JP5608645B2 (ja) | 2008-11-05 | 2014-10-15 | 学校法人慶應義塾 | 神経幹細胞製造方法 |
JP5719305B2 (ja) | 2008-11-20 | 2015-05-13 | ヤンセン バイオテツク,インコーポレーテツド | 平面支持体上での細胞付着及び培養のための方法及び組成物 |
US20100124781A1 (en) | 2008-11-20 | 2010-05-20 | Shelley Nelson | Pluripotent Stem Cell Culture on Micro-Carriers |
EP2192174B1 (en) * | 2008-11-21 | 2015-11-11 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Reprogramming cells toward a pluripotent state |
US20100150889A1 (en) | 2008-12-17 | 2010-06-17 | The Uab Research Foundation | Polycistronic Vector For Human Induced Pluripotent Stem Cell Production |
CN102317442B (zh) * | 2008-12-17 | 2014-08-13 | 斯克里普斯研究所 | 干细胞的产生和保持 |
WO2010071210A1 (ja) | 2008-12-18 | 2010-06-24 | 財団法人新産業創造研究機構 | 軟骨細胞様細胞、及びその製造方法 |
US10328103B2 (en) | 2009-01-03 | 2019-06-25 | Ray C. Wasielewski | Medical treatment composition comprising mammalian dental pulp stem cells |
US8470308B2 (en) * | 2009-01-03 | 2013-06-25 | Ray C. Wasielewski | Enhanced medical implant comprising disrupted tooth pulp and tooth particles |
WO2010090007A1 (en) | 2009-02-03 | 2010-08-12 | Keio University | Culture method of embryoid bodies and/or neural stem cells derived from human differentiated cell-derived pluripotent stem cells |
WO2010093655A2 (en) * | 2009-02-10 | 2010-08-19 | University Of Dayton | Enhanced method for producing stem-like cells from somatic cells |
EP2401372A4 (en) * | 2009-02-27 | 2012-09-19 | Univ Kyoto | NEW NUCLEAR REPROGRAMMING SUBSTANCE |
US9487756B2 (en) * | 2009-03-20 | 2016-11-08 | Mesoblast, Inc. | Production of reprogrammed pluripotent cells |
JP5637354B2 (ja) * | 2009-03-30 | 2014-12-10 | 独立行政法人産業技術総合研究所 | 精製転写因子の調製法と細胞導入技術 |
EP2420566A4 (en) | 2009-04-17 | 2014-01-15 | Univ Tohoku | METHOD FOR PREPARING HUMAN PULMONARY TISSUE STEM CELLS AND METHOD FOR INDUCING HUMAN ALVEOLAR EPITHELIAL CELL DIFFERENTIATION |
CN101613717B (zh) * | 2009-04-17 | 2012-01-11 | 中国科学院广州生物医药与健康研究院 | 用猪成纤维细胞生成诱导的多能性干细胞的方法 |
CN101580816B (zh) * | 2009-04-23 | 2012-02-29 | 中国科学院广州生物医药与健康研究院 | 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法 |
JP2010268789A (ja) | 2009-04-24 | 2010-12-02 | Kumamoto Univ | 細胞医薬の製造方法 |
EP2253700A1 (en) | 2009-05-13 | 2010-11-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
JP5765714B2 (ja) | 2009-05-29 | 2015-08-19 | 国立大学法人京都大学 | 人工多能性幹細胞の製造方法および培養方法 |
WO2010137348A1 (en) | 2009-05-29 | 2010-12-02 | Keio University | Method for selecting clone of induced pluripotent stem cells |
US9365866B2 (en) | 2009-06-03 | 2016-06-14 | National Institute Of Advanced Industrial Science And Technology | Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same |
US20110002897A1 (en) * | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
US9550975B2 (en) * | 2009-07-15 | 2017-01-24 | Mari Dezawa | SSEA-3 pluripotent stem cell isolated from body tissue |
US9399758B2 (en) | 2009-07-15 | 2016-07-26 | Mari Dezawa | SSEA3(+) pluripotent stem cell that can be isolated from body tissue |
RU2579278C2 (ru) | 2009-07-20 | 2016-04-10 | Янссен Байотек, Инк. | Популяция панкреатических эндокринных клеток-предшественников для снижения концентрации глюкозы в крови и способ дифференцировки панкреатических эндодермальных клеток |
EP2457989B1 (en) * | 2009-07-21 | 2020-11-18 | Kyoto University | Image processing device, culture observation apparatus, and image processing method |
JP5751548B2 (ja) * | 2009-08-07 | 2015-07-22 | 国立大学法人京都大学 | イヌiPS細胞及びその製造方法 |
WO2011016588A1 (en) * | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
ES2590036T3 (es) | 2009-08-12 | 2016-11-17 | Kyoto University | Método para inducir la diferenciación de células madre pluripotentes en células precursoras neurales |
CN101993495B (zh) | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
EP2468312A4 (en) | 2009-08-19 | 2014-05-14 | Univ Tohoku | SHEET FOR KERATOPLASTIES |
EP2615460B1 (en) | 2009-08-22 | 2014-06-25 | The Board Of Trustees Of The University Of the Leland Stanford Junior University | Imaging and evaluating embryos, oocytes, and stem cells |
US20110052549A1 (en) * | 2009-08-27 | 2011-03-03 | The Regents Of The University Of California | Cell culture device to differentiate stem cells in a specific orientation |
WO2011024550A1 (ja) | 2009-08-31 | 2011-03-03 | 国立大学法人大阪大学 | 口腔粘膜由来細胞を利用した誘導多能性幹細胞の効率的な製造方法 |
WO2011028880A2 (en) | 2009-09-04 | 2011-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for enhancing genome stability and telomere elongation in embryonic stem cells |
GB0915523D0 (en) * | 2009-09-07 | 2009-10-07 | Genome Res Ltd | Cells and methods for obtaining them |
JP5804280B2 (ja) | 2009-09-08 | 2015-11-04 | 国立大学法人京都大学 | 多能性幹細胞からの肥満細胞の製造方法 |
WO2011032025A2 (en) * | 2009-09-10 | 2011-03-17 | The Salk Institute For Biological Studies | Adipose-derived induced pluripotent stem cells |
AU2014240253B2 (en) * | 2009-09-15 | 2017-08-03 | The University Of Tokyo | Novel Method for Producing Differentiated Cells |
WO2011034073A1 (ja) * | 2009-09-15 | 2011-03-24 | 国立大学法人東京大学 | 分化細胞の新規製造法 |
WO2011037270A1 (en) | 2009-09-24 | 2011-03-31 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
EP2483395B1 (en) | 2009-09-30 | 2016-12-07 | Agency For Science, Technology And Research | A nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
CA2779039A1 (en) | 2009-10-29 | 2011-05-05 | Mcmaster University | Generating induced pluripotent stem cells and progenitor cells from fibroblasts |
GB0919773D0 (en) | 2009-11-12 | 2009-12-30 | Univ Nottingham | Induced pluripotent stem cell |
JP6276918B2 (ja) | 2009-11-12 | 2018-02-07 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法 |
JP2013510563A (ja) | 2009-11-13 | 2013-03-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 操作された微小胞を用いた真核細胞のリプログラミング |
EP2501803B1 (en) | 2009-11-19 | 2020-12-23 | Agency For Science, Technology And Research | Methods of enhancing pluripotentcy |
JPWO2011071118A1 (ja) | 2009-12-09 | 2013-04-22 | 国立大学法人京都大学 | ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤 |
US20130115622A1 (en) | 2009-12-14 | 2013-05-09 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
CA2784415C (en) | 2009-12-23 | 2019-06-18 | Jean Xu | Differentiation of human embryonic stem cells |
JP2011135864A (ja) * | 2009-12-30 | 2011-07-14 | Korea Univ Research & Business Foundation | Oct4及びBmi1、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法 |
US8940533B2 (en) | 2010-01-06 | 2015-01-27 | National University Corporation Tottori University | Mouse artificial chromosome vector |
JP5827220B2 (ja) | 2010-01-22 | 2015-12-02 | 国立大学法人京都大学 | 人工多能性幹細胞の樹立効率改善方法 |
EP2532741B1 (en) | 2010-02-03 | 2018-04-04 | Tetsuya Ishikawa | Induced hepatic stem cell and process for production thereof, and applications of the cell |
WO2011102531A1 (en) | 2010-02-16 | 2011-08-25 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
JP5840119B2 (ja) | 2010-02-18 | 2016-01-06 | 国立大学法人大阪大学 | 誘導多能性幹細胞の製造方法 |
CN102791851B (zh) | 2010-03-01 | 2017-07-14 | 詹森生物科技公司 | 纯化衍生自多能干细胞的细胞的方法 |
EP2542249A4 (en) | 2010-03-05 | 2013-08-07 | Tissue Genesis Inc | METHOD AND COMPOSITIONS FOR SUPPORTING TISSUE INTEGRATION AND INOCULATION OF TRANSPLANTED TISSUE AND TRANSPLANTED TREATED PENIS FABRIC WITH FAT FABRIC ACETIC COSTS |
EP2545163A4 (en) * | 2010-03-10 | 2013-11-06 | Univ Kyoto | METHOD FOR SELECTION OF INDUCED PLURIPOTENTAL STEM CELLS |
AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
JP5856949B2 (ja) | 2010-04-16 | 2016-02-10 | 学校法人慶應義塾 | 人工多能性幹細胞の製造方法 |
CA2796616A1 (en) | 2010-04-21 | 2011-10-27 | Research Development Foundation | Methods and compositions related to dopaminergic neuronal cells |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
CN102242146B (zh) * | 2010-05-10 | 2015-11-25 | 高丽大学校产学协力团 | 组合物和用其产生诱导全能干细胞的方法 |
EP3498825A1 (en) | 2010-05-12 | 2019-06-19 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
CA2804119A1 (en) | 2010-05-25 | 2011-12-01 | National Cancer Center | Induced malignant stem cells or pre-induction cancer stem cells capable of self-replication outside of an organism, production method for same, and practical application for same |
EP2580320B1 (en) | 2010-06-14 | 2018-08-01 | The Scripps Research Institute | Reprogramming of cells to a new fate |
US8932857B2 (en) | 2010-06-15 | 2015-01-13 | Kyoto University | Method for selecting reduced differentiation resistance human induced pluripotent stem cells |
EP2582792B1 (en) * | 2010-06-18 | 2018-10-31 | FUJIFILM Cellular Dynamics, Inc. | Cardiomyocyte medium with dialyzed serum |
CN103189511B (zh) | 2010-07-12 | 2016-10-12 | 国立大学法人鸟取大学 | 利用siRNA导入的新型hiPSC制作法 |
WO2012011610A1 (en) | 2010-07-21 | 2012-01-26 | Kyoto University | Method for inducing differentiation of human pluripotent stem cell into intermediate mesoderm cell |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2603583B1 (en) | 2010-08-13 | 2016-10-05 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to germ cells |
WO2012027358A1 (en) | 2010-08-23 | 2012-03-01 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
JP5930205B2 (ja) | 2010-08-26 | 2016-06-08 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化促進剤 |
US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
EP2612911B1 (en) | 2010-08-30 | 2018-01-17 | ID Pharma Co., Ltd. | Composition for inducing pluripotent stem cell, and use thereof |
BR112013004514A2 (pt) | 2010-08-31 | 2016-06-07 | Janssen Biotech Inc | diferenciação das células-tronco embrionárias humanas |
CA2809305C (en) | 2010-08-31 | 2019-06-11 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
SG10201506855RA (en) | 2010-08-31 | 2015-10-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
WO2012029994A1 (en) | 2010-09-02 | 2012-03-08 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
WO2012036299A1 (en) | 2010-09-14 | 2012-03-22 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2012037456A1 (en) | 2010-09-17 | 2012-03-22 | President And Fellows Of Harvard College | Functional genomics assay for characterizing pluripotent stem cell utility and safety |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
EP2627342B1 (en) * | 2010-10-14 | 2016-08-24 | University Of Central Florida Research Foundation, Inc. | Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium |
EP2630232A4 (en) | 2010-10-22 | 2014-04-02 | Biotime Inc | METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS |
JP6044932B2 (ja) * | 2010-10-25 | 2016-12-14 | 公立大学法人横浜市立大学 | 幹細胞の安定的維持、複製を制御するためのペプチジルプロリルイソメラーゼPin1の利用 |
WO2012060315A1 (ja) | 2010-11-02 | 2012-05-10 | 国立大学法人 熊本大学 | 腸細胞の製造方法 |
US9637732B2 (en) | 2010-11-04 | 2017-05-02 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
WO2012060109A1 (en) | 2010-11-05 | 2012-05-10 | Kyoto University | Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease |
WO2012063817A1 (ja) * | 2010-11-09 | 2012-05-18 | 独立行政法人産業技術総合研究所 | 末梢血単球由来多能性幹細胞作製方法 |
WO2012067266A1 (en) | 2010-11-17 | 2012-05-24 | Kyoto University | Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells |
EP2647384B1 (en) | 2010-12-02 | 2018-05-23 | Riken | IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH alpha CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V alpha-J alpha , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS |
US9404082B2 (en) | 2010-12-03 | 2016-08-02 | Kyoto University | Method for production of eosinophil from pluripotent stem cell |
US9506039B2 (en) | 2010-12-03 | 2016-11-29 | Kyoto University | Efficient method for establishing induced pluripotent stem cells |
JP5888852B2 (ja) * | 2010-12-08 | 2016-03-22 | 学校法人近畿大学 | 免疫不全動物を用いた細胞の製法 |
CN103380212B (zh) | 2010-12-22 | 2017-04-05 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
JP2014506453A (ja) | 2011-01-19 | 2014-03-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生得的多能性体細胞 |
WO2012098260A1 (en) | 2011-01-21 | 2012-07-26 | Axiogenesis Ag | A non-viral system for the generation of induced pluripotent stem (ips) cells |
WO2012112458A2 (en) * | 2011-02-14 | 2012-08-23 | The Regents Of The University Of California | Compositions and methods for increasing reprogramming efficiency |
EP2678425B1 (en) | 2011-02-23 | 2017-08-23 | Kyoto University | Method for producing dendritic cells from pluripotent stem cells |
AU2012220540B2 (en) | 2011-02-23 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of detecting aneuploidy in human embryos |
GB201103600D0 (en) | 2011-03-01 | 2011-04-13 | Isis Innovation | Dendritic cells |
JP2014514921A (ja) | 2011-03-30 | 2014-06-26 | 独立行政法人理化学研究所 | 機能性核酸分子、及びその利用 |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US9164093B2 (en) | 2011-03-31 | 2015-10-20 | Iheart Japan Corporation | Cardiomyocyte marker |
EP2692860A4 (en) | 2011-03-31 | 2015-05-20 | Riken | ANAPLASTIC STATE REGULATOR AND CORRESPONDING APPLICATIONS |
EP2694642B8 (en) | 2011-04-08 | 2018-10-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Method for rejuvenating cells |
US9758765B2 (en) | 2011-04-08 | 2017-09-12 | Osaka University | Modified laminin and use thereof |
WO2012141181A1 (ja) * | 2011-04-11 | 2012-10-18 | 国立大学法人京都大学 | 核初期化物質 |
JP5759536B2 (ja) | 2011-04-20 | 2015-08-05 | 国立大学法人大阪大学 | 角膜上皮分化指向性iPS細胞 |
JP6189829B2 (ja) | 2011-05-13 | 2017-08-30 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンティド・バイ・ザ・セクレタリー・フォー・ザ・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシズ | Zscan4とzscan4依存性遺伝子を利用した体細胞の直接的な再プログラム化 |
WO2012168434A1 (en) | 2011-06-08 | 2012-12-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Partial reprogramming of somatic cells to induced tissue stem (its) cells |
GB201110331D0 (en) | 2011-06-16 | 2011-08-03 | Isis Innovation | Method of cryopreserving pluripotent stem cells |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
EP2734617B1 (en) | 2011-07-22 | 2017-04-12 | Centre National De La Recherche Scientifique | Use of cellular extracts for obtaining pluripotent stem cells |
US20130029416A1 (en) | 2011-07-22 | 2013-01-31 | Tayaramma Thatava | Differentiating induced pluripotent stem cells into glucose-responsive, insulin-secreting progeny |
WO2013014929A1 (en) | 2011-07-25 | 2013-01-31 | Kyoto University | Method for screening induced pluripotent stem cells |
WO2013031826A1 (ja) * | 2011-08-29 | 2013-03-07 | 国立大学法人京都大学 | 核初期化物質 |
US9145547B2 (en) | 2011-08-30 | 2015-09-29 | Riken | Nuclear reprogrammed cells generated by introduction of a histone H2aa or TH2A gene, a histone H2ba or TH2B gene, or a phosphorylation-mimic of histone chaperon Npm2 gene, an Oct family gene and a klf family gene into a mammalian somatic cell |
US9523674B2 (en) | 2011-09-12 | 2016-12-20 | National University Corporation Kumamoto University | Method of screening for substances capable of promoting induction of induced pluripotent stem cells |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP2762560A4 (en) * | 2011-09-29 | 2015-05-20 | Univ Tokyo | PROCESS FOR INDUCING OREXINE NEURONES |
US9480695B2 (en) | 2011-09-29 | 2016-11-01 | The University Of Tokyo | Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
US20140248698A1 (en) | 2011-10-21 | 2014-09-04 | Arkray, Inc. | Method for culturing pluripotency-maintained singly dispersed cells by means of laminar flow |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
WO2013078433A1 (en) | 2011-11-23 | 2013-05-30 | University Of Hawaii | Auto-processing domains for polypeptide expression |
US20140329317A1 (en) | 2011-11-25 | 2014-11-06 | Kyoto University | Method for culturing pluripotent stem cell |
JPWO2013081188A1 (ja) | 2011-11-30 | 2015-04-27 | 独立行政法人国立がん研究センター | 誘導悪性幹細胞 |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
RU2691027C2 (ru) | 2011-12-05 | 2019-06-07 | Фэктор Байосайенс Инк. | Способы и препараты для трансфекции клеток |
US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
EP2794860B1 (en) | 2011-12-19 | 2017-05-03 | Kyoto University | Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells |
RU2705001C2 (ru) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки |
WO2013100080A1 (ja) | 2011-12-27 | 2013-07-04 | 国立大学法人大阪大学 | iPS細胞の腫瘍化を抑制することが可能な分化誘導方法 |
WO2013105098A1 (en) | 2012-01-15 | 2013-07-18 | Yeda Research And Development Co. Ltd. | Induction of dedifferentiation of mesenchymal stromal cells |
WO2013111875A1 (ja) | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
EP2823037A4 (en) | 2012-03-07 | 2015-09-16 | Janssen Biotech Inc | DEFINED MEDIA FOR THE EXPANSION AND CARE OF PLURIPOTENTAL STEM CELLS |
JP5920741B2 (ja) | 2012-03-15 | 2016-05-18 | iHeart Japan株式会社 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
EP2829605B1 (en) | 2012-03-21 | 2019-05-08 | Kyoto University | Method for screening therapeutic and/or prophylactic agents for alzheimer's disease |
US20150087594A1 (en) | 2012-03-21 | 2015-03-26 | Merck Patent Gmbh | Induced neural stem cells |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9334475B2 (en) | 2012-04-06 | 2016-05-10 | Kyoto University | Method for inducing erythropoietin-producing cell |
US10195229B2 (en) * | 2012-04-19 | 2019-02-05 | Elsa R. Flores | Generation of human induced pluripotent stem cells using nucleic acid sequences that inhibit Δ-NP63 and DGCR8 |
KR102066761B1 (ko) | 2012-05-23 | 2020-01-15 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 효율적 인공 다능성 간세포 수립 방법 |
DK3401400T3 (da) | 2012-05-25 | 2019-06-03 | Univ California | Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering |
US20130337487A1 (en) | 2012-05-31 | 2013-12-19 | Auxogyn, Inc. | In vitro embryo blastocyst prediction methods |
WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
AU2013271581B2 (en) | 2012-06-08 | 2018-08-09 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
EP3838293A1 (en) | 2012-07-11 | 2021-06-23 | Tissuetech, Inc. | Compositions containing hc-ha/ptx3 complexes and methods of use thereof |
US20150184129A1 (en) | 2012-07-17 | 2015-07-02 | Kyoto University | Novel cardiomyocyte marker |
CN113151179A (zh) | 2012-07-31 | 2021-07-23 | 阿格克斯治疗有限公司 | Hla g修饰的细胞及方法 |
EP2882445B1 (en) | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
WO2014027474A1 (ja) | 2012-08-17 | 2014-02-20 | 株式会社Clio | 心筋梗塞の修復再生を誘導する多能性幹細胞 |
JPWO2014057997A1 (ja) * | 2012-10-09 | 2016-09-05 | 仲信 林 | 初期化ペプチド及びその用途 |
JP2014082956A (ja) | 2012-10-19 | 2014-05-12 | Somar Corp | 細胞培養基材、およびそれを用いた細胞培養方法並びに多能性幹細胞の分化誘導方法 |
SG11201503167XA (en) | 2012-10-23 | 2015-05-28 | Univ Kyoto | Method of efficiently establishing induced pluripotent stem cells |
WO2014069672A1 (ja) | 2012-10-30 | 2014-05-08 | 第一三共株式会社 | Mait様細胞およびその作製方法 |
RU2711249C2 (ru) | 2012-11-01 | 2020-01-15 | Фэктор Байосайенс Инк. | Способы и продукты для экспрессии белков в клетках |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
GB201222693D0 (en) * | 2012-12-17 | 2013-01-30 | Babraham Inst | Novel method |
WO2014103137A1 (ja) | 2012-12-27 | 2014-07-03 | ソニー株式会社 | 細胞分析システム、細胞分析プログラム及び細胞分析方法 |
EP2940127B1 (en) | 2012-12-28 | 2018-07-25 | Kyoto University | Method for producing induced pluripotent stem cells, cardiomyocytes or precursor cells thereof |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
CA2896750A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
WO2014105543A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
BR112015015701A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9 |
JP6297983B2 (ja) | 2013-01-16 | 2018-03-20 | ユニバーサル・バイオ・リサーチ株式会社 | 細胞の識別方法 |
AU2014212230B2 (en) | 2013-02-01 | 2019-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs) |
CA2900741C (en) | 2013-02-01 | 2022-01-18 | Progyny, Inc. | Abnormal syngamy phenotypes observed with time lapse imaging for early identification of embryos with lower developmental potential |
JP6541577B2 (ja) | 2013-02-06 | 2019-07-10 | ユニバーシティー オブ ロチェスター | ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞 |
WO2014123242A1 (ja) | 2013-02-08 | 2014-08-14 | 国立大学法人京都大学 | 巨核球及び血小板の製造方法 |
JP6494903B2 (ja) | 2013-02-14 | 2019-04-03 | ソニー株式会社 | 分析システム、分析プログラム及び分析方法 |
JP6511606B2 (ja) | 2013-03-01 | 2019-05-15 | 株式会社生命科学インスティテュート | 多能性幹細胞を損傷部位に誘導する遊走因子を含む医薬組成物 |
EP2966163B1 (en) | 2013-03-06 | 2018-01-17 | Kyoto University | Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells |
EP2966166B1 (en) | 2013-03-08 | 2019-04-03 | Kyoto University | Promoter of differentiation of pluripotent stem cell into myocardium, which comprises egf receptor inhibitor |
WO2014153230A1 (en) | 2013-03-14 | 2014-09-25 | The Regents Of The University Of California | In vitro production of medial ganglionic eminence precursor cells |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP2977449B1 (en) | 2013-03-21 | 2020-02-26 | Kyoto University | Pluripotent stem cell for neuronal differentiation induction |
KR102164270B1 (ko) | 2013-03-25 | 2020-10-12 | 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코 | 세포의 선별 방법 |
GB201306589D0 (en) | 2013-04-11 | 2013-05-29 | Abeterno Ltd | Live cell imaging |
US10961508B2 (en) | 2013-04-12 | 2021-03-30 | Kyoto University | Method for inducing alveolar epithelial progenitor cells |
JP6429280B2 (ja) | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | 効率的な心筋細胞の誘導方法 |
EP3006559B1 (en) | 2013-05-31 | 2019-11-06 | iHeart Japan Corporation | Layered cell sheet incorporating hydrogel |
EP3008229B1 (en) | 2013-06-10 | 2020-05-27 | President and Fellows of Harvard College | Early developmental genomic assay for characterizing pluripotent stem cell utility and safety |
JP6450311B2 (ja) | 2013-06-11 | 2019-01-09 | 国立大学法人京都大学 | 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬 |
WO2014200030A1 (ja) | 2013-06-12 | 2014-12-18 | 国立大学法人京都大学 | 人工多能性幹細胞の選別方法および血球への分化誘導方法 |
JP6378183B2 (ja) | 2013-08-07 | 2018-08-22 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
SG11201602289WA (en) | 2013-08-23 | 2016-05-30 | Riken | Polypeptide exhibiting fluorescent properties, and utilization of same |
US9890360B2 (en) | 2013-08-28 | 2018-02-13 | Gifu University | Method for producing induced pluripotent stem cells |
JPWO2015030149A1 (ja) | 2013-08-29 | 2017-03-02 | 国立大学法人鳥取大学 | 細胞のアンチエイジングに関連する生体分子群 |
JP6558580B2 (ja) | 2013-09-05 | 2019-08-14 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
WO2015034710A2 (en) | 2013-09-05 | 2015-03-12 | Tempo Bioscience Inc. | Human cellular models with biosensors |
CN105849256A (zh) | 2013-09-12 | 2016-08-10 | 株式会社钟化 | 诱导多能干细胞的分化诱导方法及筛选方法 |
WO2015037706A1 (ja) | 2013-09-13 | 2015-03-19 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化を促進する化合物 |
US10975358B2 (en) | 2013-09-24 | 2021-04-13 | Id Pharma Co., Ltd. | Method for improving efficiency of inducing pluripotent stem cell |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
WO2015064754A1 (ja) | 2013-11-01 | 2015-05-07 | 国立大学法人京都大学 | 新規軟骨細胞誘導方法 |
WO2015066488A2 (en) | 2013-11-01 | 2015-05-07 | New England Biolabs, Inc. | Method for producing induced pluripotent stem cells |
WO2015068329A1 (ja) | 2013-11-08 | 2015-05-14 | ソニー株式会社 | 細胞分析システム、細胞分析プログラム及び細胞分析方法 |
WO2015069736A1 (en) | 2013-11-08 | 2015-05-14 | The Mclean Hospital Corporation | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
CN104630136B (zh) * | 2013-11-15 | 2019-10-01 | 中国科学院广州生物医药与健康研究院 | 一种制备诱导多能性干细胞的方法以及该方法中所使用的组合物及其应用 |
EP3071695A2 (en) | 2013-11-18 | 2016-09-28 | Crispr Therapeutics AG | Crispr-cas system materials and methods |
JP6536871B2 (ja) | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Fgfr3病の予防および治療剤ならびにそのスクリーニング方法 |
KR102070967B1 (ko) * | 2013-12-10 | 2020-01-29 | 한국한의학연구원 | 사군자탕을 유효성분으로 포함하는, 세포의 유도만능줄기세포로의 리프로그래밍 촉진용 조성물 및 이를 이용한 유도만능줄기세포의 제조방법 |
WO2015087231A1 (en) | 2013-12-11 | 2015-06-18 | Pfizer Limited | Method for producing retinal pigment epithelial cells |
US9994831B2 (en) | 2013-12-12 | 2018-06-12 | The Regents Of The University Of California | Methods and compositions for modifying a single stranded target nucleic acid |
US10100284B2 (en) | 2013-12-25 | 2018-10-16 | Toagosei Co. Ltd. | Method for inducing differentiation of pluripotent stem cells into endodermal cells |
EP2896688A1 (en) | 2014-01-20 | 2015-07-22 | Centre National de la Recherche Scientifique (CNRS) | A method of producing beta pancreatic cells from progenitor cells through the use of hydrogen peroxide |
EP4249036A3 (en) | 2014-01-31 | 2023-10-25 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
KR102460549B1 (ko) | 2014-03-04 | 2022-10-28 | 페이트 세러퓨틱스, 인코포레이티드 | 개선된 재프로그래밍 방법 및 세포 배양 플랫폼 |
US11066649B2 (en) | 2014-03-19 | 2021-07-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for inducing human cholangiocyte differentiation |
US10942170B2 (en) | 2014-03-20 | 2021-03-09 | Ares Trading S.A. | Quantitative measurement of human blastocyst and morula morphology developmental kinetics |
EP3121276B1 (en) | 2014-03-20 | 2019-04-17 | Kyoto University | Cardiomyocyte sorting method |
KR20160142340A (ko) | 2014-03-31 | 2016-12-12 | 아지노모토 가부시키가이샤 | 간세포용 배지 |
DK3143127T3 (da) | 2014-05-16 | 2021-09-13 | Janssen Biotech Inc | Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
US10233426B2 (en) | 2014-05-30 | 2019-03-19 | Kyoto University | Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds |
CA2947771A1 (en) | 2014-06-18 | 2015-12-23 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
EP3159354B1 (en) | 2014-06-23 | 2020-09-09 | Toagosei Co., Ltd. | Novel synthetic peptide and use thereof |
US10718781B2 (en) | 2014-07-14 | 2020-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method for identifying epitope on protein |
WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
JP6452107B2 (ja) | 2014-09-05 | 2019-01-16 | 国立大学法人 東京大学 | 糖尿病性皮膚潰瘍治療のための多能性幹細胞 |
US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
JP6598185B2 (ja) | 2014-11-07 | 2019-10-30 | 国立大学法人京都大学 | 軟骨過形成疾患の予防および治療剤ならびにそのスクリーニング方法 |
AU2015353853B2 (en) | 2014-11-25 | 2020-10-15 | President And Fellows Of Harvard College | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same |
PL3233130T3 (pl) | 2014-12-17 | 2021-11-22 | Fundacion Para La Investigacion Medica Aplicada | Konstrukty kwasów nukleinowych i wektory do terapii genowej do zastosowania w leczeniu choroby wilsona |
JP6956635B2 (ja) | 2014-12-17 | 2021-11-02 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ウィルソン病及び他の状態の処置に使用するための核酸構築物及び遺伝子治療ベクター |
JP7253692B2 (ja) | 2014-12-26 | 2023-04-07 | 国立大学法人京都大学 | 肝細胞誘導方法 |
US10077463B2 (en) | 2015-01-15 | 2018-09-18 | President And Fellows Of Harvard College | Optical selection of cells |
CN107109400B (zh) | 2015-01-16 | 2021-06-08 | 国立研究开发法人产业技术综合研究所 | 使用具有隐身性的rna的基因表达系统以及包含该rna的基因导入、表达载体 |
CA2976376A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
WO2016131137A1 (en) | 2015-02-17 | 2016-08-25 | University Health Network | Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes |
DK3059307T5 (da) | 2015-02-20 | 2022-08-29 | Inst Nat Sante Rech Med | Anvendelse af et laminin til differentiering af pluripotente celler i hepatocytcellelinier |
JP6738572B2 (ja) | 2015-03-06 | 2020-08-12 | 国立大学法人京都大学 | 肺胞上皮細胞の分化誘導法 |
JP6719449B2 (ja) | 2015-03-18 | 2020-07-08 | 小野薬品工業株式会社 | ナイーブ型多能性幹細胞の製造方法 |
WO2016165788A1 (en) | 2015-04-14 | 2016-10-20 | Uab Ferentis | Collagen mimetic peptide |
CA2982568A1 (en) * | 2015-04-14 | 2016-10-20 | Kyoto University | Method for producing stem cell clone suitable for inducing differentiation into somatic cells |
JP2016202172A (ja) | 2015-04-16 | 2016-12-08 | 国立大学法人京都大学 | 疑似膵島の製造方法 |
JP6935654B2 (ja) | 2015-04-28 | 2021-09-15 | 東亞合成株式会社 | 合成ペプチドを用いた心筋細胞の生産方法 |
US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
FR3037338B1 (fr) | 2015-06-12 | 2020-02-28 | Philippe Nirde | Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde |
WO2017002300A1 (en) | 2015-06-30 | 2017-01-05 | Sony Corporation | Information processing apparatus, information processing system, and information processing method |
JP6746945B2 (ja) | 2015-06-30 | 2020-08-26 | ソニー株式会社 | 情報処理装置、情報処理システム及び情報処理方法 |
JP6927578B2 (ja) * | 2015-07-10 | 2021-09-01 | Heartseed株式会社 | 高品質なiPS細胞の製造方法 |
US10669529B2 (en) | 2015-07-17 | 2020-06-02 | Kyoto University | Method for inducing vascular endothelial cells |
US11286454B2 (en) | 2015-08-31 | 2022-03-29 | I Peace, Inc. | Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells |
US11136551B2 (en) | 2015-09-01 | 2021-10-05 | Ncardia B.V. | In vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population |
WO2017044483A1 (en) | 2015-09-08 | 2017-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
EP3347457B1 (en) | 2015-09-08 | 2021-10-27 | FUJIFILM Cellular Dynamics, Inc. | Macs-based purification of stem cell-derived retinal pigment epithelium |
WO2017043666A1 (ja) | 2015-09-11 | 2017-03-16 | アステラス製薬株式会社 | 腎前駆細胞を製造する方法 |
JP2018532402A (ja) | 2015-09-24 | 2018-11-08 | クリスパー セラピューティクス アーゲー | Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用 |
JP6691756B2 (ja) | 2015-09-29 | 2020-05-13 | 東亞合成株式会社 | 合成ペプチドを用いた神経幹細胞の生産方法 |
WO2017059241A1 (en) | 2015-10-02 | 2017-04-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lentiviral protein delivery system for rna-guided genome editing |
WO2017062401A1 (en) | 2015-10-05 | 2017-04-13 | ORIG3N Inc. | Diagnosis and treatment of parkinson's disease based on identification and amelioration of liver dysfunction |
SG11201802957PA (en) | 2015-10-16 | 2018-05-30 | Fate Therapeutics Inc | Platform for the induction & maintenance of ground state pluripotency |
JP7061961B2 (ja) | 2015-10-20 | 2022-05-02 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 多能性幹細胞の免疫細胞への分化を誘導する方法 |
JP2016011317A (ja) * | 2015-10-21 | 2016-01-21 | 加治佐 功 | ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 |
SG11201804197RA (en) | 2015-11-18 | 2018-06-28 | Orbis Health Solutions Llc | T7 alpha viral vector system |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
GB201601503D0 (en) | 2016-01-27 | 2016-03-09 | Isis Innovation | Dendritic cells |
US20190249172A1 (en) | 2016-02-18 | 2019-08-15 | The Regents Of The University Of California | Methods and compositions for gene editing in stem cells |
EP3431584B1 (en) | 2016-03-18 | 2023-06-28 | Kyoto University | Methods for freezing an aggregate of pluripotent stem cell-derived cardiomyocytes |
WO2017164746A1 (en) | 2016-03-25 | 2017-09-28 | Pluriomics B.V. | In vivo method for differentiating human pluripotent stem cells into atrial cardiomyocytes |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
EP3444334B9 (en) | 2016-04-15 | 2023-12-20 | Kyoto University | Method for inducing antigen specific cd8 positive t cells |
US11898163B2 (en) | 2016-04-22 | 2024-02-13 | Kyoto University | Method for producing dopaminergic neuron progenitor cell |
WO2017199976A1 (ja) | 2016-05-16 | 2017-11-23 | 国立大学法人名古屋大学 | 多能性幹細胞による周産期脳障害の改善及び治療 |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2017216771A2 (en) | 2016-06-17 | 2017-12-21 | Genesis Technologies Limited | Crispr-cas system, materials and methods |
AU2017290805B2 (en) | 2016-07-01 | 2023-11-16 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
WO2018026723A1 (en) | 2016-08-01 | 2018-02-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Human induced pluripotent stem cells for high efficiency genetic engineering |
EP3494978A4 (en) | 2016-08-03 | 2020-03-11 | National University Corporation Nagoya University | IMPROVEMENT AND TREATMENT OF CHRONIC PULMONARY DISEASES USING PLURIPOTENT STEM CELLS |
KR102464099B1 (ko) | 2016-08-03 | 2022-11-08 | 히로시 야부키 | 다능성 간세포에 의한 허혈재관류 폐장애의 경감 및 치료 |
US10354218B2 (en) | 2016-08-04 | 2019-07-16 | Fanuc Corporation | System and method for iPS cell bank using internet technology |
US11259520B2 (en) | 2016-08-04 | 2022-03-01 | Fanuc Corporation | Stem cell manufacturing system, stem cell information management system, cell transport apparatus, and stem cell frozen storage apparatus |
US10373109B2 (en) | 2016-08-04 | 2019-08-06 | Fanuc Corporation | System and method for iPS cell bank using media |
US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
JP6963555B2 (ja) | 2016-09-02 | 2021-11-10 | タカラバイオ株式会社 | 多能性幹細胞からミクログリアを得る方法 |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
CN110050061A (zh) | 2016-10-05 | 2019-07-23 | 富士胶片细胞动力公司 | 从具有MeCP2破坏的诱导多能干细胞生成成熟谱系 |
JP6868250B2 (ja) | 2016-10-31 | 2021-05-12 | 国立大学法人鳥取大学 | ヒト抗体産生非ヒト動物及びそれを用いたヒト抗体作製法 |
JP7222900B2 (ja) | 2016-11-09 | 2023-02-15 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 細胞療法および創薬のための3d血管化ヒト眼組織 |
CN110114470A (zh) | 2016-12-27 | 2019-08-09 | 住友化学株式会社 | 诱导的多能性干细胞的评价方法及选择方法、以及诱导的多能性干细胞的制备方法 |
CN110199017A (zh) | 2017-01-20 | 2019-09-03 | 国立大学法人京都大学 | CD8α+β+细胞毒性T细胞的制备方法 |
US20210130785A1 (en) | 2017-01-26 | 2021-05-06 | Osaka University | Medium for inducing differentiation of stem cells into mesodermal cells and method for producing mesodermal cells |
JP7107504B2 (ja) | 2017-01-27 | 2022-07-27 | 株式会社カネカ | 内胚葉系細胞集団、及び多能性細胞から三胚葉のいずれかの細胞集団を製造する方法 |
EP3578650A4 (en) | 2017-02-06 | 2021-03-24 | National Cancer Center Japan | NEW T-LYMPHOCYTE RECEPTOR |
WO2018152120A1 (en) | 2017-02-14 | 2018-08-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
US10828330B2 (en) | 2017-02-22 | 2020-11-10 | IO Bioscience, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
CA3054119A1 (en) | 2017-02-24 | 2018-08-30 | I Peace, Inc. | Cell treatment device, suspension culture vessel, and stem cell induction method |
CN110366590A (zh) | 2017-02-27 | 2019-10-22 | 田边刚士 | 细胞处理系统及细胞处理装置 |
WO2018154788A1 (ja) | 2017-02-27 | 2018-08-30 | 剛士 田邊 | 体細胞製造システム |
EP3591040A4 (en) | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS |
EP3597734A4 (en) | 2017-03-14 | 2021-03-03 | Kyoto University | PROCESS FOR THE PRODUCTION OF AUXILIARY T LYMPHOCYTES FROM PLURIPOTENT STEM CELLS |
EP3604503A4 (en) | 2017-03-28 | 2020-12-30 | Ajinomoto Co., Inc. | ADDITIVE FOR DE-DIFFERENTIATION SUPPORT MEDIUM |
SG11201909331UA (en) | 2017-04-18 | 2019-11-28 | Fujifilm Cellular Dynamics Inc | Antigen-specific immune effector cells |
JP7336769B2 (ja) | 2017-04-19 | 2023-09-01 | シーダーズ―シナイ メディカル センター | 骨格筋ジストロフィーを治療する方法及び組成物 |
US20200197442A1 (en) * | 2017-04-26 | 2020-06-25 | Nsage Corp. | Pharmaceutical composition for prevention or treatment of alzheimer's disease, comprising stem cell secreting srage |
EP3607957A4 (en) | 2017-05-02 | 2020-12-16 | Koji Tanabe | PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION |
KR102594102B1 (ko) | 2017-05-25 | 2023-10-25 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법 |
EP3406712A1 (en) | 2017-05-26 | 2018-11-28 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Method for expanding stemness and differentiation potential of pluripotent cells |
EP3640318A4 (en) | 2017-06-14 | 2021-03-17 | Takeda Pharmaceutical Company Limited | CELL SEALING DEVICE |
JP6736772B2 (ja) | 2017-06-19 | 2020-08-05 | 公益財団法人神戸医療産業都市推進機構 | 多能性幹細胞の分化能の予測方法及びそのための試薬 |
JP6758631B2 (ja) | 2017-06-19 | 2020-09-23 | 国立大学法人大阪大学 | 角膜内皮細胞マーカー及びその利用 |
AU2018289947A1 (en) | 2017-06-20 | 2020-01-30 | Life Science Institute, Inc. | Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells |
US10660523B2 (en) | 2017-07-07 | 2020-05-26 | Hideo Ando | Light-source unit, measurement apparatus, near-infrared microscopic apparatus, optical detection method, imaging method, calculation method, functional bio-related substance, state management method, and manufacturing method |
US20210363496A1 (en) | 2017-10-17 | 2021-11-25 | Kyoto University | Method for obtaining artificial neuromuscular junction from pluripotent stem cells |
CA3079500A1 (en) | 2017-10-17 | 2019-04-25 | Hiroshima University | Pluripotent stem cells inducing osteochondral repair |
WO2019088257A1 (ja) | 2017-11-02 | 2019-05-09 | 国立大学法人鳥取大学 | 哺乳類人工染色体ベクターを利用するタンパク質の高生産方法 |
US20210363521A1 (en) | 2017-11-09 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | CRISPR/CAS Systems For Treatment of DMD |
AU2018370029A1 (en) | 2017-11-15 | 2020-07-02 | Vertex Pharmaceuticals Incorporated | Islet cell manufacturing compositions and methods of use |
BR112020010539A2 (pt) | 2017-11-30 | 2020-11-17 | Kyoto University | métodos para produção e para proliferação de células da crista neural, para produção de células nervosas, células da glia, células estromais mesenquimais, células ósseas, condrócitos, células da córnea ou células pigmentares e para cultivar células da crista neural, meio, estoque congelado, e, uso de um meio |
US11578323B2 (en) | 2017-12-14 | 2023-02-14 | Bayer Healthcare Llc | RNA-programmable endonuclease systems and their use in genome editing and other applications |
EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY |
CN111868224A (zh) | 2017-12-22 | 2020-10-30 | 国立大学法人京都大学 | 细胞培养装置,培养液抽吸器及细胞培养方法 |
US20210095311A1 (en) | 2018-03-16 | 2021-04-01 | National University Corporation Tottori University | Mouse artificial chromosome vector and use thereof |
US20210054353A1 (en) | 2018-03-19 | 2021-02-25 | Crispr Therapeutics Ag | Novel rna-programmable endonuclease systems and uses thereof |
JPWO2019182157A1 (ja) | 2018-03-19 | 2021-03-18 | 国立大学法人京都大学 | ハイドロゲルカプセル |
WO2019180247A1 (en) | 2018-03-22 | 2019-09-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for reprogramming somatic cells |
WO2019189758A1 (ja) | 2018-03-30 | 2019-10-03 | 味の素株式会社 | ポリリジン類縁体を含む、細胞増殖促進用組成物 |
JP7344486B2 (ja) | 2018-03-30 | 2023-09-14 | 国立大学法人京都大学 | 心筋細胞成熟促進剤 |
ES2966207T3 (es) | 2018-03-30 | 2024-04-18 | Orizuru Therapeutics Inc | Compuesto heterocíclico |
US20210054406A1 (en) | 2018-03-30 | 2021-02-25 | Kyoto University | Cell production method |
US11268070B2 (en) | 2018-04-16 | 2022-03-08 | Cellular Engineering Technologies, Inc. | Methods for creating integration-free, virus-free, exogenous oncogene-free IPS cells and compositions for use in such methods |
KR20210005111A (ko) | 2018-04-20 | 2021-01-13 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 안구 세포의 분화를 위한 방법 및 이의 용도 |
SG11202009855WA (en) | 2018-04-23 | 2020-11-27 | Univ Kyoto | Growth inhibitor |
US20210246427A1 (en) | 2018-04-27 | 2021-08-12 | Kaneka Corporation | Method for producing pancreatic beta cells |
WO2019236766A1 (en) | 2018-06-06 | 2019-12-12 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
CA3103663A1 (en) | 2018-06-18 | 2019-12-26 | University Of Rochester | Inhibition of re1-silencing transcription factor in the treatment of schizophrenia and other neuropsychiatric disorders |
EP3810184A2 (en) | 2018-06-21 | 2021-04-28 | University of Rochester | Methods of treating or inhibiting onset of huntington's disease |
US20210130777A1 (en) | 2018-07-13 | 2021-05-06 | Kyoto University | Method for producing gamma delta t cells |
EP3824912A4 (en) | 2018-07-19 | 2022-04-20 | Kyoto University | PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE |
WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
US20210292708A1 (en) | 2018-08-03 | 2021-09-23 | Kyoto University | Cell production method |
AU2019320072A1 (en) | 2018-08-10 | 2021-02-25 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
WO2020032179A1 (ja) | 2018-08-10 | 2020-02-13 | 国立大学法人京都大学 | Cd3陽性細胞の製造方法 |
CN112639111B (zh) | 2018-08-10 | 2023-07-21 | 国立大学法人京都大学 | 使用阳离子性脂质的转染心肌细胞的方法 |
CN112839667A (zh) | 2018-08-14 | 2021-05-25 | 国立研究开发法人国立国际医疗研究中心 | 褐色脂肪细胞上清、其制备法及使用 |
EP3842513A4 (en) | 2018-08-20 | 2022-06-29 | I Peace, Inc. | Cell incubator |
EP3842526A4 (en) | 2018-08-20 | 2022-05-25 | I Peace, Inc. | METHOD FOR CULTIVATING OR INDUCING CELLS |
SG11202101565XA (en) | 2018-08-22 | 2021-03-30 | Univ Kyoto | Method for producing enteric neural precursors |
BR112021003640A2 (pt) | 2018-08-31 | 2021-05-18 | Noile-Immune Biotech, Inc. | célula t, medicamento, vetor de expressão, e, métodos para produzir uma célula de t car e para tratar câncer |
SG11202102748WA (en) | 2018-09-19 | 2021-04-29 | Takeda Pharmaceuticals Co | Insulin-producing cells |
WO2020075823A1 (ja) | 2018-10-10 | 2020-04-16 | 国立大学法人鳥取大学 | 微小核細胞融合法による目的dnaを含む動物細胞の作製方法 |
WO2020075822A1 (ja) | 2018-10-10 | 2020-04-16 | 国立大学法人鳥取大学 | 外来染色体を含むヒト人工多能性幹細胞の製造方法 |
US20210292791A1 (en) | 2018-10-12 | 2021-09-23 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
WO2020080270A1 (ja) | 2018-10-15 | 2020-04-23 | 公立大学法人横浜市立大学 | 栄養組成物 |
WO2020090903A1 (ja) | 2018-10-31 | 2020-05-07 | 国立大学法人京都大学 | 中内胚葉系への分化抵抗性が解除された多能性幹細胞の作製方法 |
AU2019375450A1 (en) | 2018-11-07 | 2021-06-17 | Vivet Therapeutics | Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2) |
EP4257155A3 (en) | 2018-11-16 | 2024-02-28 | Encoded Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
KR20210095885A (ko) | 2018-11-19 | 2021-08-03 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 생분해성 조직 대체 임플란트 및 그의 용도 |
EA202191463A1 (ru) | 2018-11-28 | 2021-10-13 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде |
JP7016102B2 (ja) | 2018-12-06 | 2022-02-04 | キリンホールディングス株式会社 | T細胞又はnk細胞の製造方法、t細胞又はnk細胞の培養用培地、t細胞又はnk細胞の培養方法、未分化t細胞の未分化状態を維持する方法及びt細胞又はnk細胞の増殖促進剤 |
AU2019396450A1 (en) | 2018-12-11 | 2021-06-24 | University Of Rochester | Methods of treating schizophrenia and other neuropsychiatric disorders |
WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
EP3903884A4 (en) | 2018-12-26 | 2023-01-25 | Kirin Holdings Kabushiki Kaisha | MODIFIED TCR AND MANUFACTURING PROCESS THEREOF |
CN113272319A (zh) | 2018-12-27 | 2021-08-17 | 国立大学法人京都大学 | T细胞受体的变体 |
TW202045718A (zh) | 2019-02-01 | 2020-12-16 | 國立大學法人京都大學 | 細胞的檢測方法 |
WO2020167822A2 (en) | 2019-02-13 | 2020-08-20 | University Of Rochester | Gene networks that mediate remyelination of the human brain |
US20220145255A1 (en) | 2019-02-26 | 2022-05-12 | Tohoku University | Method for producing osteoblast cluster using ips cells |
JP2020141588A (ja) | 2019-03-05 | 2020-09-10 | ファナック株式会社 | 細胞製造システム |
EP4219700A1 (en) | 2019-03-07 | 2023-08-02 | The Regents of the University of California | Crispr-cas effector polypeptides and methods of use thereof |
WO2020209959A1 (en) | 2019-03-08 | 2020-10-15 | Crispr Therapeutics Ag | Nucleobase-editing fusion protein systems, compositions, and uses thereof |
EP3937963A2 (en) | 2019-03-12 | 2022-01-19 | CRISPR Therapeutics AG | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
US20220169977A1 (en) | 2019-03-29 | 2022-06-02 | Kaneka Corporation | Cell population including pluripotent stem cells and production method thereof |
WO2020204149A1 (ja) | 2019-03-29 | 2020-10-08 | 公立大学法人横浜市立大学 | スクリーニング方法および毒性評価法 |
SG11202111123SA (en) | 2019-04-10 | 2021-11-29 | Orizuru Therapeutics Inc | Method for producing biological tissue-like structure |
CN113692442A (zh) | 2019-04-17 | 2021-11-23 | 学校法人庆应义塾 | 诱导多能干细胞的制造方法以及试剂盒 |
US20210047649A1 (en) | 2019-05-08 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crispr/cas all-in-two vector systems for treatment of dmd |
CN113811316A (zh) | 2019-05-15 | 2021-12-17 | 味之素株式会社 | 神经嵴细胞或角膜上皮细胞的纯化方法 |
CA3141455A1 (en) | 2019-05-20 | 2020-11-26 | Ajinomoto Co., Inc. | Expansion culture method for cartilage or bone precursor cells |
WO2020250927A1 (ja) | 2019-06-10 | 2020-12-17 | アイ ピース, インコーポレイテッド | 赤血球除去装置、単核球回収器、細胞培養装置、細胞培養システム、細胞培養方法、及び単核球の回収方法 |
US20220306981A1 (en) | 2019-06-10 | 2022-09-29 | I Peace, Inc. | Erythrocyte removal device, mononuclear cell collector, cell culture device, cell culture system, cell culture method, and method for collecting mononuclear cells |
WO2020250913A1 (ja) | 2019-06-11 | 2020-12-17 | 国立大学法人京都大学 | 腎間質細胞の製造方法 |
JP2022539169A (ja) | 2019-06-25 | 2022-09-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | ベータ細胞の分化の向上 |
WO2020262351A1 (ja) | 2019-06-28 | 2020-12-30 | アイ ピース, インコーポレイテッド | 細胞塊分割器、細胞塊分割器の製造方法、及び細胞塊の分割方法 |
CN113811597B (zh) | 2019-06-28 | 2024-06-18 | 爱平世股份有限公司 | 细胞培养装置的应用 |
WO2021014515A1 (ja) | 2019-07-19 | 2021-01-28 | 東京エレクトロン株式会社 | 細胞の分化状態の評価方法 |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
WO2021030424A1 (en) | 2019-08-13 | 2021-02-18 | Semma Therapeutics, Inc. | Pancreatic differentiation |
WO2021033699A1 (ja) | 2019-08-20 | 2021-02-25 | 国立大学法人京都大学 | 心筋細胞の富化方法 |
WO2021038996A1 (ja) | 2019-08-29 | 2021-03-04 | ファナック株式会社 | 細胞製造装置及びその製造方法 |
JP7297272B2 (ja) | 2019-08-29 | 2023-06-26 | ファナック株式会社 | 細胞製造装置 |
CN114341340A (zh) | 2019-08-29 | 2022-04-12 | 发那科株式会社 | 细胞制造装置及其系统 |
KR20220069096A (ko) | 2019-10-01 | 2022-05-26 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 요관아 선단부 세포의 단리 방법 |
US20240124846A1 (en) | 2019-10-21 | 2024-04-18 | Orizuru Therapeutics, Inc. | Growth inhibitor |
US20220387507A1 (en) | 2019-10-31 | 2022-12-08 | Life Science Institute, Inc. | Therapy for interstitial cystitis by pluripotent stem cells |
WO2021085576A1 (ja) | 2019-11-01 | 2021-05-06 | 国立大学法人京都大学 | T細胞の製造方法 |
US20220403307A1 (en) | 2019-11-06 | 2022-12-22 | I Peace, Inc. | Cell culture device |
JPWO2021095811A1 (ja) | 2019-11-12 | 2021-05-20 | ||
IL293189A (en) | 2019-11-25 | 2022-07-01 | Univ Kyoto | A primary cell bank of t cells |
JP7058431B2 (ja) | 2019-12-12 | 2022-04-22 | 国立大学法人千葉大学 | 巨核球および血小板を含む凍結乾燥製剤 |
FR3105260A1 (fr) | 2019-12-20 | 2021-06-25 | Centre National De La Recherche Scientifique (Cnrs) | Modèle organoïde cardiaque vascularisé apres incorporation de cardiomyocytes dérivés de cellules souches pluripotentes induites humaines |
JP2023516632A (ja) | 2020-02-28 | 2023-04-20 | 武田薬品工業株式会社 | 多能性幹細胞からナチュラルキラー細胞を産生するための方法 |
CN115551994A (zh) | 2020-03-11 | 2022-12-30 | 倍特博有限公司 | 产生肝细胞的方法 |
AU2021233179A1 (en) | 2020-03-13 | 2022-09-29 | Goliver Therapeutics | Hepatic stem-like cells for the treatment and/or the prevention of fulminant liver disorders |
JP7418759B2 (ja) | 2020-03-18 | 2024-01-22 | ファナック株式会社 | 顕微鏡観察システム |
AU2021239654A1 (en) | 2020-03-19 | 2022-10-27 | Orizuru Therapeutics, Inc. | Cardiomyocyte purification method |
EP4123016A4 (en) | 2020-03-19 | 2024-06-19 | Orizuru Therapeutics, Inc. | METHOD FOR THE PURIFICATION OF CARDIOMYOCYTES |
JPWO2021193360A1 (ja) | 2020-03-24 | 2021-09-30 | ||
CA3178684A1 (en) | 2020-03-31 | 2021-10-07 | Sky Pharma Co., Ltd. | Method for screening for, method for producing, and method for designing drug active ingredients |
JPWO2021200901A1 (ja) | 2020-03-31 | 2021-10-07 | ||
US20230203445A1 (en) | 2020-05-26 | 2023-06-29 | Healios K.K. | Hypoimmunogenic cells |
WO2021241668A1 (ja) | 2020-05-28 | 2021-12-02 | 武田薬品工業株式会社 | 均一なサイズの細胞凝集体の大量製造方法 |
MX2022015002A (es) | 2020-05-29 | 2023-03-03 | Fujifilm Cellular Dynamics Inc | Bicapa del epitelio pigmentario de la retina y fotorreceptores y uso de los mismos. |
WO2021243256A1 (en) | 2020-05-29 | 2021-12-02 | FUJIFILM Cellular Dynamics, Inc. | Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof |
WO2021250058A2 (en) | 2020-06-12 | 2021-12-16 | Bayer Aktiengesellschaft | CRISPR-Cas12a DIRECTED RANDOM MUTAGENESIS AGENTS AND METHODS |
EP4170020A1 (en) | 2020-06-17 | 2023-04-26 | Kyoto University | Chimeric antigen receptor-expressing immunocompetent cells |
EP4180516A4 (en) | 2020-07-13 | 2024-01-17 | Kyoto University | SKELETON MUSCLE PRECURSOR CELLS AND METHOD FOR PURIFICATION THEREOF, COMPOSITION FOR THE TREATMENT OF MYOGENIC DISEASES AND METHOD FOR PRODUCING SKELETON MUSCLE PRECURSOR CELLS CONTAINING CELL GROUPS |
CN116134130A (zh) | 2020-07-20 | 2023-05-16 | 学校法人爱知医科大学 | 多能细胞的未分化维持培养用组合物、多能细胞的未分化维持培养用培养基、多能细胞的未分化状态下的维持培养方法、和多能细胞的制造方法 |
US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
CN116323917A (zh) | 2020-08-18 | 2023-06-23 | 国立大学法人京都大学 | 人原始生殖细胞/人原始生殖细胞样细胞的维持扩增方法 |
WO2022050419A1 (ja) | 2020-09-04 | 2022-03-10 | Heartseed株式会社 | iPS細胞の品質改善剤、iPS細胞の製造方法、iPS細胞、及びiPS細胞製造用組成物 |
JP2023542728A (ja) | 2020-09-29 | 2023-10-11 | ジェネトン | ユートロフィン調節エレメント内に変異を誘導することによる細胞におけるユートロフィン発現の増強、及びその治療的使用 |
EP4243839A1 (en) | 2020-11-13 | 2023-09-20 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
WO2022107877A1 (ja) | 2020-11-20 | 2022-05-27 | オリヅルセラピューティクス株式会社 | 成熟化剤 |
US20220162288A1 (en) | 2020-11-25 | 2022-05-26 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
EP4263818A1 (en) | 2020-12-16 | 2023-10-25 | Universitat Pompeu Fabra | Therapeutic lama2 payload for treatment of congenital muscular dystrophy |
JP2022099262A (ja) | 2020-12-22 | 2022-07-04 | アイ ピース,インコーポレイテッド | 細胞の培養器及び細胞の培養方法 |
WO2022138101A1 (ja) | 2020-12-23 | 2022-06-30 | 三井化学株式会社 | 培養部材およびその用途 |
US20240091382A1 (en) | 2020-12-23 | 2024-03-21 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
AU2021409196A1 (en) | 2020-12-25 | 2023-08-03 | Id Pharma Co., Ltd. | Method for producing naive human ips cells from somatic cells |
WO2022163466A1 (ja) * | 2021-01-26 | 2022-08-04 | アイ ピース, インコーポレイテッド | オリゴデンドロサイトの作製方法 |
CN116829697A (zh) | 2021-02-09 | 2023-09-29 | 千纸鹤治疗公司 | 促熟剂 |
US20240158740A1 (en) | 2021-03-09 | 2024-05-16 | National University Corporation Tokyo Medical And Dental University | Cell cluster production method |
WO2022196714A1 (ja) | 2021-03-17 | 2022-09-22 | アステラス製薬株式会社 | 塩基性繊維芽細胞増殖因子(bFGF)遺伝子が導入されたペリサイト |
EP4060026A1 (en) | 2021-03-19 | 2022-09-21 | Technische Universität Dresden | Ex-vivo proliferation of human phagocytic cells |
EP4134086A1 (en) | 2021-08-12 | 2023-02-15 | Technische Universität Dresden | Human macrophages resistant to tumor-induced repolarization |
CA3213153A1 (en) | 2021-03-19 | 2022-09-22 | Technische Universitat Dresden | Human macrophages resistant to tumor-induced repolarization |
EP4314246A1 (en) | 2021-04-01 | 2024-02-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Liver organoid manufacturing methods, liver organoids obtained with the same, and uses thereof |
AU2022255421A1 (en) | 2021-04-08 | 2023-10-26 | Noile-Immune Biotech Inc. | Method for activating t-cells |
WO2022230919A1 (ja) | 2021-04-28 | 2022-11-03 | 国立大学法人 東京医科歯科大学 | 細胞の製造方法 |
EP4331673A1 (en) | 2021-04-30 | 2024-03-06 | Riken | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
WO2022236187A1 (en) | 2021-05-07 | 2022-11-10 | Children's Hospital Los Angeles | Methods for making stem cell-derived enteric neural crest cells and their use in enteric neuropathy treatment |
JP2024520413A (ja) | 2021-05-26 | 2024-05-24 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 多能性幹細胞における遺伝子の迅速なサイレンシングを防止するための方法 |
AU2022280062A1 (en) | 2021-05-28 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to generate macular, central and peripheral retinal pigment epithelial cells |
WO2022251477A1 (en) | 2021-05-28 | 2022-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells |
EP4352205A1 (en) | 2021-06-07 | 2024-04-17 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Method for generating highly functional hepatocytes by differentiating hepatoblasts |
CA3222761A1 (en) | 2021-06-10 | 2022-12-15 | Ajinomoto Co., Inc. | Method for producing mesenchymal stem cells |
AU2022290382A1 (en) | 2021-06-11 | 2023-11-23 | Bayer Aktiengesellschaft | Type v rna programmable endonuclease systems |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
BR112023026141A2 (pt) | 2021-06-15 | 2024-03-05 | Takeda Pharmaceuticals Co | Métodos para produzir uma população de células enriquecida em células nk, para produzir células nk derivadas de células-tronco pluripotentes induzidas, para tratar um sujeito em necessidade de terapia de células e para produzir uma população de células compreendendo células progenitoras hematopoiéticas cd34+, e, populações de células nk e de células não classificadas |
CN117561328A (zh) | 2021-06-29 | 2024-02-13 | 国立大学法人佐贺大学 | iPS细胞来源的软骨细胞结构体的制造方法 |
JPWO2023286834A1 (ja) | 2021-07-15 | 2023-01-19 | ||
JPWO2023286832A1 (ja) | 2021-07-15 | 2023-01-19 | ||
WO2023003025A1 (ja) | 2021-07-21 | 2023-01-26 | 国立大学法人京都大学 | 網膜組織の製造方法 |
JPWO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | ||
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
CN118159646A (zh) | 2021-09-13 | 2024-06-07 | 富士胶片细胞动力公司 | 产生定向心脏祖细胞的方法 |
CA3234008A1 (en) | 2021-09-27 | 2023-03-30 | Kyoto University | Method for producing t cell |
WO2023053220A1 (ja) | 2021-09-28 | 2023-04-06 | 公益財団法人京都大学iPS細胞研究財団 | 多能性幹細胞の製造方法 |
US20230292719A1 (en) | 2021-10-20 | 2023-09-21 | University Of Rochester | Humanized chimeras for the prospective assessment of cell addition and replacement therapies |
AU2022371414A1 (en) | 2021-10-20 | 2024-05-02 | University Of Copenhagen | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
CA3233935A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se |
WO2023070019A1 (en) | 2021-10-21 | 2023-04-27 | Vertex Pharmaceuticals Incorporated | Hypoimmune cells |
WO2023077140A2 (en) | 2021-11-01 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Stem cell derived pancreatic islet differentiation |
WO2023081633A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
CN118265792A (zh) | 2021-11-11 | 2024-06-28 | 希里欧斯株式会社 | 基因修饰多能干细胞、来自其的免疫活性细胞、它们的制造方法和它们的用途 |
EP4389902A1 (en) | 2021-11-15 | 2024-06-26 | National University Corporation Tottori University | Method for producing human artificial chromosome vector in human cells |
JPWO2023090361A1 (ja) | 2021-11-16 | 2023-05-25 | ||
WO2023090372A1 (ja) | 2021-11-16 | 2023-05-25 | 学校法人東京薬科大学 | プロモーター活性化配列、そのプロモーター活性化配列を含む発現ベクター、及びその発現ベクターを含む哺乳動物細胞 |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023150557A1 (en) | 2022-02-01 | 2023-08-10 | University Of Rochester | Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods |
WO2023167986A1 (en) | 2022-03-02 | 2023-09-07 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating hearing loss |
WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
WO2023211857A1 (en) | 2022-04-25 | 2023-11-02 | Lineage Cell Therapeutics, Inc. | Methods and compositions for treating vision loss |
WO2023215455A1 (en) | 2022-05-05 | 2023-11-09 | University Of Rochester | Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023247532A1 (en) | 2022-06-21 | 2023-12-28 | Institut National de la Santé et de la Recherche Médicale | A method for producing a bioengineered mammal induced pluripotent stem cell-derived cardiac organoid |
US20240003871A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Cellular Dynamics, Inc. | Ipsc-derived astrocytes and methods of use thereof |
EP4338745A1 (en) | 2022-09-14 | 2024-03-20 | Technische Universität Dresden | Allogeneic human macrophages for cell therapy |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
WO2024129743A2 (en) | 2022-12-13 | 2024-06-20 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US70292A (en) * | 1867-10-29 | Petess | ||
US4650761A (en) * | 1981-11-27 | 1987-03-17 | Eli Lilly And Company | Method for stabilizing and selecting recombinant DNA containing host cell |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US6140111A (en) | 1987-12-11 | 2000-10-31 | Whitehead Institute For Biomedical Research | Retroviral gene therapy vectors and therapeutic methods based thereon |
US7070994B2 (en) | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
US5591624A (en) | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
JP2886547B2 (ja) | 1988-07-26 | 1999-04-26 | 協和醗酵工業株式会社 | ノイラミニダーゼの製造法 |
EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規dnaならびにそれを含有する発現プラスミド |
JP2897295B2 (ja) | 1989-12-14 | 1999-05-31 | 味の素株式会社 | レトロウィルス高生産用dna構築物及びレトロウィルス高生産用細胞株 |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5817491A (en) | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
FR2707091B1 (fr) | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
US5534423A (en) | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US6013517A (en) | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
EP0787200B1 (en) | 1994-10-28 | 2005-04-20 | The Trustees Of The University Of Pennsylvania | Improved adenovirus and methods of use thereof |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5637456A (en) | 1995-02-17 | 1997-06-10 | The University Of Texas, Board Of Regents | Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US5830725A (en) | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
US5744320A (en) | 1995-06-07 | 1998-04-28 | Promega Corporation | Quenching reagents and assays for enzyme-mediated luminescence |
CN1208438A (zh) | 1995-07-28 | 1999-02-17 | 玛丽·柯里癌症治疗中心 | 转运蛋白及其应用 |
CA2232506A1 (en) | 1995-09-22 | 1997-03-27 | Medical Research Council | Improvements in or relating to mutagenesis of nucleic acids |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
FR2751345B1 (fr) | 1996-07-16 | 1998-09-18 | Univ Paris Curie | Lignees d'encapsidation hautement productrices |
US6255071B1 (en) | 1996-09-20 | 2001-07-03 | Cold Spring Harbor Laboratory | Mammalian viral vectors and their uses |
US6025192A (en) | 1996-09-20 | 2000-02-15 | Cold Spring Harbor Laboratory | Modified retroviral vectors |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US6416959B1 (en) | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
WO1999010536A1 (en) | 1997-08-22 | 1999-03-04 | Yale University | A process to study changes in gene expression in granulocytic cells |
JPH11115328A (ja) * | 1997-10-16 | 1999-04-27 | Dainippon Printing Co Ltd | 熱転写受像シート及びその製造方法 |
US6835567B1 (en) * | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
US20020174013A1 (en) | 1998-04-17 | 2002-11-21 | Viztec Inc., A Florida Corporation | Chip card advertising method and system |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
KR20000006334A (ko) | 1998-06-26 | 2000-01-25 | 이선경 | 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터 |
US6485959B1 (en) | 1998-10-07 | 2002-11-26 | Cedars Sinai Medical Center | Cell preconditioning and cryopresevation medium |
JP2002527101A (ja) | 1998-10-16 | 2002-08-27 | ノバルティス アクチエンゲゼルシャフト | ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進 |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
IL142748A0 (en) * | 1998-11-09 | 2002-03-10 | Univ Monash | Embryonic stem cells |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
US6312949B1 (en) | 1999-03-26 | 2001-11-06 | The Salk Institute For Biological Studies | Regulation of tyrosine hydroxylase expression |
US6773920B1 (en) | 1999-03-31 | 2004-08-10 | Invitrogen Corporation | Delivery of functional protein sequences by translocating polypeptides |
JP3904451B2 (ja) | 1999-06-01 | 2007-04-11 | 俊雄 北村 | パッケージング細胞 |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US6881825B1 (en) | 1999-09-01 | 2005-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues |
AU7611500A (en) | 1999-09-24 | 2001-04-24 | Abt Holding Company | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
US20030161817A1 (en) | 2001-03-28 | 2003-08-28 | Young Henry E. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US7544509B2 (en) | 2000-01-24 | 2009-06-09 | Mcgill University | Method for preparing stem cell preparations |
US6395546B1 (en) | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
AU6319901A (en) | 2000-05-17 | 2001-11-26 | Geron Corp | Neural progenitor cell populations |
AU6842001A (en) | 2000-06-15 | 2001-12-24 | Tanja Dominko | Pluripotent mammalian cells |
DE10031179A1 (de) | 2000-06-27 | 2002-01-31 | Amaxa Gmbh | Verfahren zur Einbringung von Nukleinsäuren und anderen biologisch aktiven Molekülen in den Kern höherer eukaryontischer Zellen mit Hilfe elektrischen Stroms |
CA2417454A1 (en) | 2000-07-31 | 2002-02-07 | Active Motif | Peptide-mediated delivery of molecules into cells |
JP2002065261A (ja) | 2000-08-30 | 2002-03-05 | Mitsubishi Kasei Institute Of Life Sciences | 生殖細胞の取得方法 |
EP1313642B1 (de) | 2000-08-31 | 2006-04-26 | Edwin Lundgren | Steuervorrichtung für einen lenkdrachen an einem boot |
US20020127715A1 (en) | 2000-11-27 | 2002-09-12 | Nissim Benvenisty | Transfection of human embryonic stem cells |
US20080268054A1 (en) | 2000-12-04 | 2008-10-30 | Eugene Bell | Dermal derived human stem cells and compositions and methods thereof |
JP4223284B2 (ja) | 2001-01-02 | 2009-02-12 | ステムロン インコーポレイテッド | 予め選抜されたイムノタイプおよび/またはジェノタイプを有するホモ接合性幹細胞群の製造方法、該細胞由来の移植に適切な細胞、並びにこれらを用いた材料および方法 |
US20040077079A1 (en) * | 2001-01-31 | 2004-04-22 | Peter Storgaard | Improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods |
JP2003009854A (ja) | 2001-04-09 | 2003-01-14 | Kyowa Hakko Kogyo Co Ltd | エンブリオイドボディ形成方法及びその用途 |
DE50201240D1 (de) | 2001-04-23 | 2004-11-11 | Amaxa Gmbh | Pufferlössung für die elektroporation und verfahren umfassend die verwendung derselben |
DE10119901A1 (de) | 2001-04-23 | 2002-10-24 | Amaxa Gmbh | Schaltungsanordnung zur Einbringung von Nukleinsäuren und anderen biologisch aktiven Molekülen in den Kern höherer eukaryontischer Zellen mit Hilfe elektrischen Stroms |
US7250255B2 (en) | 2001-05-31 | 2007-07-31 | Shinya Yamanaka | Genes with ES cell-specific expression |
US20030044976A1 (en) | 2001-08-27 | 2003-03-06 | Advanced Cell Technology | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
JPWO2003027281A1 (ja) | 2001-09-20 | 2005-01-06 | 協和醗酵工業株式会社 | 骨格筋間質由来多分化能幹細胞 |
EP1437403A4 (en) | 2001-09-21 | 2004-10-27 | Japan Science & Tech Corp | METHOD FOR PATTERNING REPROGRAMMING FACTOR, METHOD OF PATTERNED REPROGRAMMING FACTOR, METHOD FOR USE OF REPROGRAMMING FACTOR, METHOD FOR DIFFERENTIATING AND SIFE-INGENATING FAN |
JP2004248505A (ja) * | 2001-09-21 | 2004-09-09 | Norio Nakatsuji | 移植抗原の一部または全てを欠除したes細胞由来の未分化な体細胞融合細胞およびその製造 |
US7588937B2 (en) | 2001-10-03 | 2009-09-15 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
DE10162080A1 (de) | 2001-12-10 | 2003-06-26 | Albrecht Mueller | Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential |
ATE464373T1 (de) * | 2001-12-21 | 2010-04-15 | Mount Sinai Hospital Corp | Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung |
AU2003238620B2 (en) | 2002-01-31 | 2008-11-06 | Asahi Techno Glass Corporation | Liquid for frozen storage of primate embryo stem cells and frozen storage method |
WO2003068937A2 (en) * | 2002-02-13 | 2003-08-21 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
ES2198216B1 (es) * | 2002-07-02 | 2005-04-16 | Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). | Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones. |
US7422736B2 (en) | 2002-07-26 | 2008-09-09 | Food Industry Research And Development Institute | Somatic pluripotent cells |
US20040048297A1 (en) | 2002-07-30 | 2004-03-11 | Gene Logic, Inc. | Nucleic acid detection assay control genes |
JP3736517B2 (ja) * | 2002-11-13 | 2006-01-18 | 学校法人近畿大学 | 体細胞核初期化因子 |
AU2003901099A0 (en) | 2003-03-11 | 2003-03-27 | Es Cell International Pte Ltd. | Methods of inducing differentiation of stem cells |
WO2004085632A1 (ja) * | 2003-03-25 | 2004-10-07 | Japan Science And Technology Agency | 幹細胞の分化誘導および分化能の制御 |
CN1536076A (zh) * | 2003-04-09 | 2004-10-13 | 中国人民解放军军事医学科学院野战输 | 成年人骨髓间充质干细胞体外扩增和定向诱导分化为心肌样细胞的方法 |
US9567591B2 (en) | 2003-05-15 | 2017-02-14 | Mello Biotechnology, Inc. | Generation of human embryonic stem-like cells using intronic RNA |
JPWO2004101775A1 (ja) | 2003-05-16 | 2006-07-13 | 協和醗酵工業株式会社 | 新規な成体組織由来の幹細胞およびその用途 |
US20050019801A1 (en) | 2003-06-04 | 2005-01-27 | Curis, Inc. | Stem cell-based methods for identifying and characterizing agents |
FR2859219B1 (fr) * | 2003-09-02 | 2005-10-14 | Alain Privat | Procede de production de neurones a partir de cellules d'une lignee cellulaire |
JP2005095027A (ja) | 2003-09-22 | 2005-04-14 | Reprocell Inc | 細胞の未分化状態マーカープロモーターおよびその利用 |
CA2542130A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Cell genomically modified to produce polypeptides with an altered glycosylation pattern |
EP1682150B1 (en) | 2003-11-10 | 2012-12-26 | The Scripps Research Institute | Compositions and methods for inducing cell dedifferentiation |
US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
WO2005053601A2 (en) | 2003-12-01 | 2005-06-16 | Technion Research & Development Foundation Ltd. | Methods of generating stem cells and embryonic bodies carrying disease-causing mutations and methods of using same for studying genetic disorders |
US20050233446A1 (en) * | 2003-12-31 | 2005-10-20 | Parsons Xuejun H | Defined media for stem cell culture |
US7964401B2 (en) | 2004-02-19 | 2011-06-21 | Kyoto University | Screening method for somatic cell nuclear reprogramming substance affecting ECAT2 and ECAT3 |
US7892835B2 (en) | 2004-03-23 | 2011-02-22 | Daiichi Sankyo Company, Limited | Pluripotent stem cell growing method |
WO2005100548A1 (ja) * | 2004-03-30 | 2005-10-27 | Kyoto University | 精巣細胞由来多能性幹細胞の製造方法 |
WO2005117557A2 (en) | 2004-06-01 | 2005-12-15 | San Diego State University Foundation | Expression system |
US20070202592A1 (en) | 2004-07-08 | 2007-08-30 | Yasuo Kitagawa | Pluripotent Cells Distributed Ubiquitously In Animal Tissue, Which Proliferate Selectively In Lower-Serum Culture |
WO2006084229A2 (en) | 2004-07-15 | 2006-08-10 | Primegen Biotech, Llc | Use of nuclear material to therapeutically reprogram differentiated cells |
US20060088599A1 (en) | 2004-08-02 | 2006-04-27 | Prasad Paras N | Amino functionalized ORMOSIL nanoparticles as delivery vehicles |
US7803920B2 (en) | 2004-09-29 | 2010-09-28 | Shinya Yamanaka | ECAT16 gene expressed specifically in ES cells and utilization of the same |
US20060095319A1 (en) | 2004-10-29 | 2006-05-04 | Cardwell Carlzo B | Marketing and compensation method |
US20060182724A1 (en) | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
WO2006093172A1 (ja) | 2005-02-28 | 2006-09-08 | Foundation For Biomedical Research And Innovation | 成体幹細胞の体外増幅方法 |
US20070033061A1 (en) | 2005-04-05 | 2007-02-08 | Achaogen, Inc. | Business methods for commercializing antimicrobial and cytotoxic compounds |
WO2007026255A2 (en) | 2005-06-22 | 2007-03-08 | Universitetet I Oslo | Dedifferentiated cells and methods of making and using dedifferentiated cells |
AU2006275479B2 (en) * | 2005-08-01 | 2012-11-29 | Nupotential, Inc. | Production of reprogrammed cells with restored potential |
JP2009515515A (ja) | 2005-11-11 | 2009-04-16 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ | 細胞の再プログラム化および遺伝子改変 |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
WO2007097494A1 (en) | 2006-02-27 | 2007-08-30 | Imgen Co., Ltd. | De-differentiation of astrocytes into neural stem cell using bmi-1 |
US20090252711A1 (en) | 2006-05-11 | 2009-10-08 | Andrew Craig Boquest | Stem Cells And Methods Of Making And Using Stem Cells |
WO2008030610A2 (en) | 2006-09-08 | 2008-03-13 | Michigan State University | Human transcriptome corresponding to human oocytes and use of said genes or the corresponding polypeptides to trans-differentiate somatic cells |
JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
US20080132803A1 (en) | 2006-11-30 | 2008-06-05 | Hyman Friedlander | Method and system for doing business by mining the placental-chord complex |
WO2008089351A1 (en) | 2007-01-17 | 2008-07-24 | Wisconsin Alumni Research Foundation | Improved culture of stem cells |
WO2008105566A1 (en) | 2007-02-27 | 2008-09-04 | Korea Stem Cell Bank | System for providing stem cell services using internet and method thereof |
WO2008105630A1 (en) | 2007-02-27 | 2008-09-04 | Procell Therapeutics Inc. | Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells |
EP2137296A2 (en) | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
MX348010B (es) | 2007-04-07 | 2017-05-23 | Whitehead Inst Biomedical Res | Reprogramacion de celulas somaticas. |
CN101772580B (zh) | 2007-05-29 | 2015-11-25 | 克里斯多佛·B·里德 | 专能细胞群的生产和使用方法 |
CA2688539A1 (en) | 2007-05-30 | 2008-12-11 | The General Hospital Corporation | Methods of generating pluripotent cells from somatic cells |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
US20120282229A1 (en) | 2007-08-01 | 2012-11-08 | Christian Kannemeier | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
EP2190976A4 (en) | 2007-08-10 | 2010-10-20 | Univ Dayton | METHOD FOR PRODUCING PLURIPOTENTAL STEM CELL LENGTH CELLS |
ES2589122T3 (es) | 2007-08-31 | 2016-11-10 | Whitehead Institute For Biomedical Research | Estimulación de la ruta de la Wnt en la reprogramación de células somáticas |
WO2009057831A1 (ja) | 2007-10-31 | 2009-05-07 | Kyoto University | 核初期化方法 |
US20110151447A1 (en) | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
WO2009067563A1 (en) | 2007-11-19 | 2009-05-28 | The Regents Of The University Of California | Generation of pluripotent cells from fibroblasts |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
AU2008286249B2 (en) | 2007-12-10 | 2013-10-10 | Kyoto University | Efficient method for nuclear reprogramming |
US20090191171A1 (en) | 2008-01-18 | 2009-07-30 | Yupo Ma | Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination |
KR101481164B1 (ko) | 2008-01-30 | 2015-01-09 | 주식회사 미래셀바이오 | 체세포 유래 다능성 줄기세포의 제조 방법 |
WO2009102983A2 (en) | 2008-02-15 | 2009-08-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
JP2011516042A (ja) | 2008-03-17 | 2011-05-26 | へルムホルツ・ツェントルム・ミュンヘン−ドイチェス・フォルシュングスツェントルム・ヒューア・ゲズントハイト・ウント・ウムヴェルト(ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング) | 部位特異的組み換えを用いて無ベクター誘導多能性幹(iPS)細胞を作製するベクターおよびその方法 |
AU2009225665B9 (en) | 2008-03-17 | 2015-01-15 | The Scripps Research Institute | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
CN101250502A (zh) | 2008-04-01 | 2008-08-27 | 中国科学院上海生命科学研究院 | 一种诱导的多潜能干细胞的制备方法 |
CN101550406B (zh) | 2008-04-03 | 2016-02-10 | 北京大学 | 制备多潜能干细胞的方法,试剂盒及用途 |
US20100021437A1 (en) | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
EP2268809B1 (en) | 2008-05-02 | 2019-02-06 | Kyoto University | Method of nuclear reprogramming |
EP2128245A1 (en) | 2008-05-27 | 2009-12-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Generation of induced pluripotent stem (iPS) cells |
EP3112456A1 (en) | 2008-06-04 | 2017-01-04 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using non-viral approach |
KR101372752B1 (ko) | 2008-07-31 | 2014-03-14 | 고꾸리츠 다이가꾸호오징 기후다이가꾸 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
US20100062534A1 (en) | 2008-09-09 | 2010-03-11 | The General Hospital Corporation | Inducible lentiviral vectors for reprogramming somatic cells |
US8268620B2 (en) | 2008-10-24 | 2012-09-18 | Wisconsin Alumni Research Foundation | OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells |
-
2006
- 2006-12-06 EP EP10154819A patent/EP2206724A1/en not_active Withdrawn
- 2006-12-06 CN CN201310015158.1A patent/CN103113463B/zh active Active
- 2006-12-06 EP EP23165497.1A patent/EP4223769A3/en active Pending
- 2006-12-06 US US12/086,479 patent/US8048999B2/en active Active
- 2006-12-06 EA EA201000858A patent/EA018039B1/ru not_active IP Right Cessation
- 2006-12-06 MX MX2008007654A patent/MX2008007654A/es active IP Right Grant
- 2006-12-06 EP EP10154821.2A patent/EP2206778B1/en active Active
- 2006-12-06 EP EP18174008.5A patent/EP3418297B1/en active Active
- 2006-12-06 KR KR1020087017015A patent/KR101420740B1/ko active IP Right Grant
- 2006-12-06 NZ NZ569530A patent/NZ569530A/en unknown
- 2006-12-06 ZA ZA200804673A patent/ZA200804673B/xx unknown
- 2006-12-06 ES ES06834636T patent/ES2367525T3/es active Active
- 2006-12-06 CN CN200680048227.7A patent/CN101356270B/zh active Active
- 2006-12-06 CA CA2632142A patent/CA2632142C/en active Active
- 2006-12-06 EP EP10154817.0A patent/EP2208786B1/en active Active
- 2006-12-06 CN CN201010126185.2A patent/CN101864392B/zh active Active
- 2006-12-06 PT PT06834636T patent/PT1970446E/pt unknown
- 2006-12-06 DK DK06834636.0T patent/DK1970446T3/da active
- 2006-12-06 MX MX2011013772A patent/MX352337B/es unknown
- 2006-12-06 AU AU2006325975A patent/AU2006325975B2/en active Active
- 2006-12-06 EA EA200870046A patent/EA014166B1/ru not_active IP Right Cessation
- 2006-12-06 CN CN201410006027.1A patent/CN103773804A/zh active Pending
- 2006-12-06 BR BRPI0619794A patent/BRPI0619794B8/pt active IP Right Grant
- 2006-12-06 WO PCT/JP2006/324881 patent/WO2007069666A1/ja active Application Filing
- 2006-12-06 EP EP06834636A patent/EP1970446B1/en active Active
- 2006-12-06 JP JP2007550210A patent/JP5098028B2/ja active Active
-
2008
- 2008-05-20 JP JP2008131577A patent/JP4183742B1/ja active Active
- 2008-06-03 IL IL191903A patent/IL191903A/en active IP Right Grant
-
2009
- 2009-03-10 JP JP2009056750A patent/JP4411363B2/ja active Active
- 2009-03-10 JP JP2009056747A patent/JP4411362B2/ja active Active
- 2009-03-10 JP JP2009056748A patent/JP5248371B2/ja active Active
- 2009-03-10 JP JP2009056749A patent/JP5467223B2/ja active Active
- 2009-03-12 HK HK09102406.5A patent/HK1125131A1/xx unknown
- 2009-04-17 HK HK09103541.9A patent/HK1125967A1/xx unknown
-
2011
- 2011-04-12 JP JP2011088113A patent/JP5603282B2/ja active Active
-
2013
- 2013-08-12 JP JP2013167725A patent/JP5943324B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5943324B2 (ja) | 誘導多能性幹細胞 | |
US20220048963A1 (en) | Nuclear reprogramming factor and induced pluripotent stem cells | |
US8278104B2 (en) | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 | |
CA2695522C (en) | Method of nuclear reprogramming | |
US8129187B2 (en) | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 | |
JP5626619B2 (ja) | 効率的な核初期化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20090428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100707 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130410 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5248371 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160419 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |